3b:I[281230,["/_next/static/immutable/chunks/0l5c-zsrs2aic.js","/_next/static/immutable/chunks/3_n0rk2989-8h.js","/_next/static/immutable/chunks/3ofw495lt1gr1.js","/_next/static/immutable/chunks/3tofdpg99uc12.js","/_next/static/immutable/chunks/2rzojj6zgb9d9.js","/_next/static/immutable/chunks/42jxjvozn2thc.js","/_next/static/immutable/chunks/1jp6nkbajpbfs.js","/_next/static/immutable/chunks/3jn_lf7v27x-6.js","/_next/static/immutable/chunks/33qq2-hg37d0b.js","/_next/static/immutable/chunks/15isb0svrppbz.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/0asz50g5_lfq9.js","/_next/static/immutable/chunks/30ia-cxa0yoyc.js","/_next/static/immutable/chunks/3ghibkczd0agr.js","/_next/static/immutable/chunks/20mjl75wrar8n.js","/_next/static/immutable/chunks/3nxreg9fiyt2y.js","/_next/static/immutable/chunks/0c04lgvo3p78i.js","/_next/static/immutable/chunks/1u78gf_avpn77.js"],"PaperListPageClient"] 42:I[70339,["/_next/static/immutable/chunks/355lxm8rh3fxr.js"],"IconMark"] 3c:T789,The guideline panel agreed on 16 recommendations, of which 1 is a strong recommendation, 9 are conditional recommendations, and 6 were identified as knowledge gaps. In adult patients with moderate-to-severely active CD, the AGA recommends the use of infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab, or upadacitinib over no treatment, and suggests the use of certolizumab pegol or vedolizumab over no treatment. In individuals who are naïve to advanced therapies, the AGA suggests using a higher efficacy medication (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, or guselkumab) rather than a lower-efficacy medication (certolizumab pegol or upadacitinib). In individuals who have previously been exposed to 1 or more advanced therapies, the AGA suggests using a higher efficacy medication (adalimumab, risankizumab, guselkumab, or upadacitinib) or intermediate efficacy medication (ustekinumab or mirikizumab) rather than a lower efficacy medication (vedolizumab or certolizumab pegol). In adult outpatients with moderate-to-severely active CD, the AGA suggests against using thiopurine monotherapy for induction of remission, but suggests using thiopurine monotherapy over no treatment for maintenance of (typically corticosteroid-induced) remission. The AGA suggests using subcutaneous methotrexate for induction and maintenance of remission, but suggests against using oral methotrexate. The AGA suggests using combination therapy with infliximab and thiopurines over infliximab monotherapy, particularly in those naïve to thiopurines. The AGA also suggests using initial advanced therapy over step therapy involving corticosteroids and/or immunomodulators in patients with moderate-to-severely active CD. The panel also proposed key implementation considerations for optimal use of these medications, identified several knowledge gaps, and areas for future research.3d:Ta0c,This American Gastroenterological Association (AGA) living guideline is intended to support practitioners in the pharmacologic management of moderate-to-severely active Crohn's disease (CD). A multidisciplinary panel of clinical experts and methodologists used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework to prioritize clinical questions, identify patient-centered outcomes, conduct an evidence synthesis, and develop recommendations. The guideline panel agreed on 16 recommendations, of which 1 is a strong recommendation, 9 are conditional recommendations, and 6 were identified as knowledge gaps. In adult patients with moderate-to-severely active CD, the AGA recommends the use of infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab, or upadacitinib over no treatment, and suggests the use of certolizumab pegol or vedolizumab over no treatment. In individuals who are naïve to advanced therapies, the AGA suggests using a higher efficacy medication (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, or guselkumab) rather than a lower-efficacy medication (certolizumab pegol or upadacitinib). In individuals who have previously been exposed to 1 or more advanced therapies, the AGA suggests using a higher efficacy medication (adalimumab, risankizumab, guselkumab, or upadacitinib) or intermediate efficacy medication (ustekinumab or mirikizumab) rather than a lower efficacy medication (vedolizumab or certolizumab pegol). In adult outpatients with moderate-to-severely active CD, the AGA suggests against using thiopurine monotherapy for induction of remission, but suggests using thiopurine monotherapy over no treatment for maintenance of (typically corticosteroid-induced) remission. The AGA suggests using subcutaneous methotrexate for induction and maintenance of remission, but suggests against using oral methotrexate. The AGA suggests using combination therapy with infliximab and thiopurines over infliximab monotherapy, particularly in those naïve to thiopurines. The AGA also suggests using initial advanced therapy over step therapy involving corticosteroids and/or immunomodulators in patients with moderate-to-severely active CD. The panel also proposed key implementation considerations for optimal use of these medications, identified several knowledge gaps, and areas for future research. This guideline provides a comprehensive, patient-centered, evidence-based approach to the pharmacologic management of patients with moderate-to-severely active CD.3e:T710,Many biologic therapies are available for moderate-to-severe plaque psoriasis. A systematic literature review and network meta-analysis (NMA) was conducted to compare the efficacy of the interleukin (IL)-23 inhibitor, tildrakizumab, with other biologics at up to 28 weeks of treatment. The literature search was conducted on January 22, 2024, searching MEDLINE, Embase, and CENTRAL for randomized controlled trials (RCTs) investigating the comparative efficacy and safety of biologics in adult Asian patients with moderate-to-severe plaque psoriasis. NMAs were conducted for ≥ 75%, ≥ 90%, and 100% reduction in Psoriasis Area and Severity Index score (PASI 75, 90, and 100) and achieving a Physician Global Assessment (PGA) score of 0 or 1 after the induction period (12 and 16 weeks) and mid-term (28 weeks) follow-up. NMAs were conducted using the Bayesian framework outlined in the National Institute of Clinical Excellence guidelines. Nineteen RCTs conducted in China, Japan, Korea, and Taiwan with 11 different biologics were included. At Week 12, tildrakizumab had lower efficacy compared to other biologics. Between Weeks 12 and 28, the proportion of patients achieving PASI 75/90/100 with tildrakizumab increased from 60.77% to 81.84%, from 38.54% to 71.23%, and from 6.97% to 22.64%, respectively. At Week 28, tildrakizumab efficacy was comparable to other biologic therapies studied here, including tumor necrosis factor-alpha (TNFα), IL-17, IL-12/IL-23, and other IL-23 inhibitors. The efficacy of tildrakizumab improved over time, which underscores the importance of evaluating the sustained efficacy of tildrakizumab over the long term. Combined with low dosing frequency, tildrakizumab offers an effective treatment option for patients with moderate-to-severe plaque psoriasis.3f:T760,ABSTRACTMany biologic therapies are available for moderate‐to‐severe plaque psoriasis. A systematic literature review and network meta‐analysis (NMA) was conducted to compare the efficacy of the interleukin (IL)‐23 inhibitor, tildrakizumab, with other biologics at up to 28 weeks of treatment. The literature search was conducted on January 22, 2024, searching MEDLINE, Embase, and CENTRAL for randomized controlled trials (RCTs) investigating the comparative efficacy and safety of biologics in adult Asian patients with moderate‐to‐severe plaque psoriasis. NMAs were conducted for ≥ 75%, ≥ 90%, and 100% reduction in Psoriasis Area and Severity Index score (PASI 75, 90, and 100) and achieving a Physician Global Assessment (PGA) score of 0 or 1 after the induction period (12 and 16 weeks) and mid‐term (28 weeks) follow‐up. NMAs were conducted using the Bayesian framework outlined in the National Institute of Clinical Excellence guidelines. Nineteen RCTs conducted in China, Japan, Korea, and Taiwan with 11 different biologics were included. At Week 12, tildrakizumab had lower efficacy compared to other biologics. Between Weeks 12 and 28, the proportion of patients achieving PASI 75/90/100 with tildrakizumab increased from 60.77% to 81.84%, from 38.54% to 71.23%, and from 6.97% to 22.64%, respectively. At Week 28, tildrakizumab efficacy was comparable to other biologic therapies studied here, including tumor necrosis factor‐alpha (TNFα), IL‐17, IL‐12/IL‐23, and other IL‐23 inhibitors. The efficacy of tildrakizumab improved over time, which underscores the importance of evaluating the sustained efficacy of tildrakizumab over the long term. Combined with low dosing frequency, tildrakizumab offers an effective treatment option for patients with moderate‐to‐severe plaque psoriasis.40:Tbcc,Patients with psoriasis may require a switch to another therapy due to high treatment costs, primary effectiveness failure, biologic fatigue, or adverse effects associated with the initial biologic treatment; however, the availability of evidence for the effectiveness and safety of interclass biologic switching for the treatment of psoriasis is unknown. To investigate the effectiveness and safety of psoriasis treatment after the failure of initial biologic therapy, particularly when patients switch to a second biologic. PubMed, Embase, and the Cochrane Library were searched from inception through January 25, 2025. The study included randomized clinical trials (RCTs) of patients with plaque psoriasis aged 18 years or older involving crossover or switching from 1 biologic agent to another initial biologic within the same or different drug class. Two researchers independently screened the records and abstracted data using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guideline. Data were pooled using random-effects models. The prespecified primary end point was psoriasis area and severity index (PASI) 90. Secondary end points included clinician- and patient-reported outcomes (PROMs) and safety. Clinical effectiveness was evaluated based on the PASI responses (PASI 75, 90, and 100) and the Investigator's and Physician's Global Assessments scores of 0 or 1 and body surface area of 1% or less. PROMs included the dermatology life quality index and psoriasis symptoms and signs diary. Safety concerns included adverse events (AEs), serious AEs, severe AEs, treatment-related AEs, and specific AEs. Twenty-four RCTs involving 12 661 patients with psoriasis and 8 switching categories were analyzed. Significant differences observed in PASI 90 between week 4 and week 0 (odds ratio [OR], 6.53; 95% CI, 2.58-16.51). Substantial disparities were noted across various PASI response metrics, specifically PASI 90 (OR, 28.61; 95% CI, 12.89-63.47), PASI 75 (OR, 11.11; 95% CI, 5.95-20.75), and PASI 100 (OR, 18.76; 95% CI, 8.37-42.01). No difference exists in safety outcomes between the end point and week 0, including in serious AEs (OR, 1.63; 95% CI, 0.72-3.69), severe AEs (OR, 1.40; 95% CI, 0.61-3.26), and treatment-related AEs (OR, 1.79; 95% CI, 0.41-7.88). The highest risk of infection was associated with switching from anti-TNF-α agents to anti-interleukin (IL)-23p19, anti-IL-17A, or anti-IL-12/23p40 agents, with infection rates of 0.62%, 0.54% and 0.39%, respectively. This systematic review and meta-analysis found that interclass biologic switching was effective in a significant number of patients. With the introduction of biologics with diverse mechanisms of action, these options may become viable and potentially superior. However, further confirmatory data from larger patient cohorts and longer follow-up periods are required to obtain more conclusive results. Our results highlight the importance of vigilance for infections when switching biologics.41:Tef0,ImportancePatients with psoriasis may require a switch to another therapy due to high treatment costs, primary effectiveness failure, biologic fatigue, or adverse effects associated with the initial biologic treatment; however, the availability of evidence for the effectiveness and safety of interclass biologic switching for the treatment of psoriasis is unknown.ObjectiveTo investigate the effectiveness and safety of psoriasis treatment after the failure of initial biologic therapy, particularly when patients switch to a second biologic.Data SourcesPubMed, Embase, and the Cochrane Library were searched from inception through January 25, 2025.Study SelectionThe study included randomized clinical trials (RCTs) of patients with plaque psoriasis aged 18 years or older involving crossover or switching from 1 biologic agent to another initial biologic within the same or different drug class.Data Extraction and SynthesisTwo researchers independently screened the records and abstracted data using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guideline. Data were pooled using random-effects models.Main Outcomes and MeasuresThe prespecified primary end point was psoriasis area and severity index (PASI) 90. Secondary end points included clinician- and patient-reported outcomes (PROMs) and safety. Clinical effectiveness was evaluated based on the PASI responses (PASI 75, 90, and 100) and the Investigator’s and Physician’s Global Assessments scores of 0 or 1 and body surface area of 1% or less. PROMs included the dermatology life quality index and psoriasis symptoms and signs diary. Safety concerns included adverse events (AEs), serious AEs, severe AEs, treatment-related AEs, and specific AEs.ResultsTwenty-four RCTs involving 12 661 patients with psoriasis and 8 switching categories were analyzed. Significant differences observed in PASI 90 between week 4 and week 0 (odds ratio [OR], 6.53; 95% CI, 2.58-16.51). Substantial disparities were noted across various PASI response metrics, specifically PASI 90 (OR, 28.61; 95% CI, 12.89-63.47), PASI 75 (OR, 11.11; 95% CI, 5.95-20.75), and PASI 100 (OR, 18.76; 95% CI, 8.37-42.01). No difference exists in safety outcomes between the end point and week 0, including in serious AEs (OR, 1.63; 95% CI, 0.72-3.69), severe AEs (OR, 1.40; 95% CI, 0.61-3.26), and treatment-related AEs (OR, 1.79; 95% CI, 0.41-7.88). The highest risk of infection was associated with switching from anti−TNF-α agents to anti−interleukin (IL)-23p19, anti−IL-17A, or anti−IL-12/23p40 agents, with infection rates of 0.62%, 0.54% and 0.39%, respectively.Conclusions and RelevanceThis systematic review and meta-analysis found that interclass biologic switching was effective in a significant number of patients. With the introduction of biologics with diverse mechanisms of action, these options may become viable and potentially superior. However, further confirmatory data from larger patient cohorts and longer follow-up periods are required to obtain more conclusive results. Our results highlight the importance of vigilance for infections when switching biologics.28:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"IL-12/23 Inhibitor: Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on IL-12/23 Inhibitor (modality). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/modality/IL-12%2F23%20Inhibitor\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Modalities\",\"item\":\"https://www.reachrx.ai/hub/tag/modality\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"IL-12/23 Inhibitor\",\"item\":\"https://www.reachrx.ai/hub/tag/modality/IL-12%2F23%20Inhibitor\"}]}}"}}]],["$","$L3b",null,{"title":"IL-12/23 Inhibitor: Research & Clinical Takeaways","description":"Review evidence by treatment modality: IL-12/23 Inhibitor — concise summaries and practical next steps.","papers":[{"doi":"10.1093/ibd/izag177","pmid":"42850680","title":"Differential long-term efficacy of biologic and small-molecule therapies by disease location in moderate-to-severe luminal Crohn's disease: a systematic review and network meta-analysis","journal_title":"Inflammatory Bowel Diseases","journal_issn":"1078-0998","published_at":"2026-10-08T00:00:00.000Z","url":"https://doi.org/10.1093/ibd/izag177","source_score":7,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-10-19T13:51:34.486Z","updated_at":"2026-10-19T13:51:34.486Z","tags":[{"paper_doi":"10.1093/ibd/izag177","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1093/ibd/izag177","tag_type":"brand","value":"Entyvio","value_numeric":null},{"paper_doi":"10.1093/ibd/izag177","tag_type":"brand","value":"Humira","value_numeric":null},{"paper_doi":"10.1093/ibd/izag177","tag_type":"brand","value":"Omvoh","value_numeric":null},{"paper_doi":"10.1093/ibd/izag177","tag_type":"brand","value":"Remicade","value_numeric":null},{"paper_doi":"10.1093/ibd/izag177","tag_type":"brand","value":"Rinvoq","value_numeric":null},{"paper_doi":"10.1093/ibd/izag177","tag_type":"brand","value":"Skyrizi","value_numeric":null},{"paper_doi":"10.1093/ibd/izag177","tag_type":"brand","value":"Stelara","value_numeric":null},{"paper_doi":"10.1093/ibd/izag177","tag_type":"brand","value":"Tremfya","value_numeric":null},{"paper_doi":"10.1093/ibd/izag177","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1093/ibd/izag177","tag_type":"condition","value":"Crohn's Disease","value_numeric":null},{"paper_doi":"10.1093/ibd/izag177","tag_type":"generic","value":"adalimumab","value_numeric":null},{"paper_doi":"10.1093/ibd/izag177","tag_type":"generic","value":"guselkumab","value_numeric":null},{"paper_doi":"10.1093/ibd/izag177","tag_type":"generic","value":"infliximab","value_numeric":null},{"paper_doi":"10.1093/ibd/izag177","tag_type":"generic","value":"mirikizumab","value_numeric":null},{"paper_doi":"10.1093/ibd/izag177","tag_type":"generic","value":"risankizumab","value_numeric":null},{"paper_doi":"10.1093/ibd/izag177","tag_type":"generic","value":"upadacitinib","value_numeric":null},{"paper_doi":"10.1093/ibd/izag177","tag_type":"generic","value":"ustekinumab","value_numeric":null},{"paper_doi":"10.1093/ibd/izag177","tag_type":"generic","value":"vedolizumab","value_numeric":null},{"paper_doi":"10.1093/ibd/izag177","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1093/ibd/izag177","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1093/ibd/izag177","tag_type":"modality","value":"IL-12/23 Inhibitor","value_numeric":null},{"paper_doi":"10.1093/ibd/izag177","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.1093/ibd/izag177","tag_type":"modality","value":"Integrin Inhibitor","value_numeric":null},{"paper_doi":"10.1093/ibd/izag177","tag_type":"modality","value":"JAK Inhibitor","value_numeric":null},{"paper_doi":"10.1093/ibd/izag177","tag_type":"modality","value":"TNF Inhibitor","value_numeric":null},{"paper_doi":"10.1093/ibd/izag177","tag_type":"sample_size","value":"n=4697","value_numeric":4697},{"paper_doi":"10.1093/ibd/izag177","tag_type":"study_design","value":"Systematic Review and Network Meta-Analysis","value_numeric":null},{"paper_doi":"10.1093/ibd/izag177","tag_type":"warning","value":"Guselkumab's superiority in isolated ileal disease and upadacitinib's advantage in colonic disease are derived from subgroup-level data; these findings should be interpreted with caution until confirmed in prospective, location-stratified trials","value_numeric":null},{"paper_doi":"10.1093/ibd/izag177","tag_type":"warning","value":"Location-stratified subgroup analyses in network meta-analyses rely on indirect comparisons and may not fully account for differences in trial populations, baseline disease severity, or prior treatment exposure across included RCTs","value_numeric":null},{"paper_doi":"10.1093/ibd/izag177","tag_type":"warning","value":"The included trials used varying definitions of endoscopic response and clinical remission, and some trials used re-randomization designs, which may affect comparability of results across agents","value_numeric":null}],"summaries":{"what_studied":"A systematic review and Bayesian network meta-analysis of 18 RCTs (n=4,697 adults) evaluated long-term efficacy (week 52) of biologic and small-molecule therapies—adalimumab, infliximab, vedolizumab, ustekinumab, mirikizumab, risankizumab, guselkumab, and upadacitinib—in moderate-to-severe luminal Crohn's disease, stratified by Montreal disease location (ileal, colonic, ileocolonic).","key_result":"Clinical remission rates were lowest in isolated ileal disease; guselkumab 200/100 mg was the only agent statistically superior to placebo for ileal maintenance remission at week 52 (RR 3.4, 95% CI 1.3–8.9). Upadacitinib 30 mg showed the strongest colonic efficacy, with significantly higher remission in colonic vs. ileal disease (efficacy ratio 4.6, 95% CI 1.7–12.6) and ileocolonic vs. ileal (efficacy ratio 3.45, 95% CI 1.2–9.6); no location-dependent differences were found for other agents.","limitations":"NMA indirect comparisons are subject to heterogeneity across trial populations and designs; subgroup data by disease location were not uniformly reported across all included RCTs, potentially limiting precision of location-stratified estimates.","practice_takeaway":"When selecting therapy for moderate-to-severe luminal Crohn's disease, consider disease location: upadacitinib 30 mg appears most effective for colonic and ileocolonic disease, while guselkumab shows a signal in isolated ileal disease. These findings support incorporating Montreal disease location into shared treatment decision-making."}},{"doi":"10.1016/j.cgh.2026.09.038","pmid":"42838315","title":"EFFICACY AND SAFETY OF ADVANCED THERAPIES AS INDUCTION THERAPY FOR ULCERATIVE COLITIS: AN UPDATED SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS","journal_title":"Clinical Gastroenterology and Hepatology","journal_issn":"1542-3565","published_at":"2026-10-06T00:00:00.000Z","url":"https://doi.org/10.1016/j.cgh.2026.09.038","source_score":7,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-10-13T13:58:52.159Z","updated_at":"2026-10-13T13:58:52.159Z","tags":[{"paper_doi":"10.1016/j.cgh.2026.09.038","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.09.038","tag_type":"brand","value":"Omvoh","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.09.038","tag_type":"brand","value":"Rinvoq","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.09.038","tag_type":"brand","value":"Skyrizi","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.09.038","tag_type":"brand","value":"Stelara","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.09.038","tag_type":"brand","value":"Tremfya","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.09.038","tag_type":"brand","value":"Xeljanz","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.09.038","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.09.038","tag_type":"condition","value":"Ulcerative Colitis","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.09.038","tag_type":"generic","value":"guselkumab","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.09.038","tag_type":"generic","value":"mirikizumab","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.09.038","tag_type":"generic","value":"obefazimod","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.09.038","tag_type":"generic","value":"risankizumab","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.09.038","tag_type":"generic","value":"tofacitinib","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.09.038","tag_type":"generic","value":"upadacitinib","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.09.038","tag_type":"generic","value":"ustekinumab","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.09.038","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.09.038","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.09.038","tag_type":"modality","value":"IL-12/23 Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.09.038","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.09.038","tag_type":"modality","value":"Integrin Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.09.038","tag_type":"modality","value":"JAK Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.09.038","tag_type":"modality","value":"S1P Receptor Modulator","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.09.038","tag_type":"modality","value":"TNF Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.09.038","tag_type":"sample_size","value":"n=33","value_numeric":33},{"paper_doi":"10.1016/j.cgh.2026.09.038","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.09.038","tag_type":"study_design","value":"Systematic Review and Network Meta-Analysis","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.09.038","tag_type":"warning","value":"Network meta-analysis relies heavily on indirect comparisons; head-to-head trial data between most agents are lacking, which limits certainty of rankings","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.09.038","tag_type":"warning","value":"Obefazimod and subcutaneous guselkumab were included as late-stage investigational agents and are not yet universally approved, which may limit immediate clinical applicability","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.09.038","tag_type":"warning","value":"Safety confidence ratings were generally lower than efficacy ratings; clinicians should interpret SAE and AELD rankings with caution","value_numeric":null}],"summaries":{"what_studied":"A systematic review and NMA of 33 phase 3 RCTs evaluated 17 advanced therapies as induction therapy for moderate-to-severe UC, comparing clinical remission, endoscopic improvement, and safety outcomes (SAEs, AELDs, serious infections), stratified by prior AT exposure.","key_result":"Upadacitinib ranked highest for clinical remission (RR 6.90; 95% CI 3.54–12.45; P-score 0.95; high confidence) and endoscopic improvement (RR 5.29; 95% CI 3.38–8.28; P-score 0.97; moderate confidence); anti-p19 inhibitors (risankizumab, subcutaneous guselkumab, mirikizumab) had the most favorable safety profiles for SAEs and AELDs.","limitations":"Confidence in safety estimates was lower across therapies; indirect comparisons dominate due to limited head-to-head trials; some agents (obefazimod, subcutaneous guselkumab) are in late-stage development and not yet broadly approved.","practice_takeaway":"Upadacitinib should be considered a top induction option for both AT-naïve and AT-experienced moderate-to-severe UC patients. When safety is the primary concern—especially for SAEs and treatment discontinuations—anti-p19 inhibitors (risankizumab, mirikizumab, guselkumab SC) are preferred choices."}},{"doi":"10.1093/bjd/ljag403","pmid":"42791206","title":"Efficacy and Safety of Risankizumab in Paediatric Patients With Psoriasis in the OptIMMize-1 Phase III Study","journal_title":"British Journal of Dermatology","journal_issn":"0007-0963","published_at":"2026-09-26T00:00:00.000Z","url":"https://doi.org/10.1093/bjd/ljag403","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-10-03T13:52:37.286Z","updated_at":"2026-10-03T13:52:37.286Z","tags":[{"paper_doi":"10.1093/bjd/ljag403","tag_type":"age_group","value":"pediatric","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag403","tag_type":"brand","value":"Skyrizi","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag403","tag_type":"brand","value":"Stelara","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag403","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag403","tag_type":"condition","value":"Psoriasis","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag403","tag_type":"generic","value":"risankizumab","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag403","tag_type":"generic","value":"ustekinumab","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag403","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag403","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag403","tag_type":"modality","value":"IL-12/23 Inhibitor","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag403","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag403","tag_type":"sample_size","value":"n=137","value_numeric":137},{"paper_doi":"10.1093/bjd/ljag403","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag403","tag_type":"study_design","value":"Phase III Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag403","tag_type":"warning","value":"Part 2 is the only randomised, controlled portion of the study; Parts 1, 3, and 4 are open-label single-arm designs, which limits the strength of comparative conclusions across the full trial","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag403","tag_type":"warning","value":"Patients were not stratified by age subgroup within 'paediatric,' so it is unclear how findings apply to younger children vs. adolescents specifically","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag403","tag_type":"warning","value":"The ustekinumab comparator arm in Part 2 was small (n=28), reducing the power to detect differences in most outcomes other than PASI100","value_numeric":null}],"summaries":{"what_studied":"The OptIMMize-1 phase III study (NCT04435600) evaluated the efficacy and safety of risankizumab (an IL-23 inhibitor) vs. ustekinumab over 52 weeks in paediatric patients with moderate-to-severe psoriasis across 4 study parts, with Part 2 randomising patients 2:1 to risankizumab vs. ustekinumab.","key_result":"At week 16 in Part 2 (risankizumab n=54 vs. ustekinumab n=28), sPGA0/1 rates were 79.6% vs. 75.0%, PASI75 rates were 85.2% vs. 85.7%, PASI90 rates were 64.8% vs. 60.7%, and PASI100 rates were notably higher with risankizumab (40.7% vs. 17.9%); efficacy was maintained or improved at week 52, with a safety profile consistent with adult studies.","limitations":"The study was open-label in three of four parts, limiting blinding; the comparator arm (ustekinumab) in Part 2 was relatively small (n=28); and no placebo-controlled comparison was included.","practice_takeaway":"Risankizumab appears effective and well tolerated in paediatric moderate-to-severe psoriasis, with meaningful skin clearance, itch, and quality-of-life improvements sustained to 52 weeks, supporting its use as an advanced therapy option in this population."}},{"doi":"10.2340/actadv.v106.adv-2026-0797","pmid":"42708646","title":"Current Evidence on IL-17 and IL-(12)/23 Inhibitor Safety during Pregnancy in Psoriasis: A Call for Harmonized Data Collection","journal_title":"Acta Dermato-Venereologica","journal_issn":"1651-2057","published_at":"2026-09-08T00:00:00.000Z","url":"https://doi.org/10.2340/actadv.v106.adv-2026-0797","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-12T06:20:17.230Z","updated_at":"2026-09-12T06:20:17.230Z","tags":[{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"brand","value":"Bimzelx","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"brand","value":"Cosentyx","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"brand","value":"Siliq","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"brand","value":"Skyrizi","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"brand","value":"Stelara","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"brand","value":"Taltz","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"brand","value":"Tremfya","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"condition","value":"Psoriasis","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"bimekizumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"brodalumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"guselkumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"ixekizumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"mirikizumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"risankizumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"secukinumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"tildrakizumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"ustekinumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"modality","value":"IL-12/23 Inhibitor","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"modality","value":"IL-17 Inhibitor","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"sample_size","value":"n=5962","value_numeric":5962},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"study_design","value":"Systematic Review","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"warning","value":"Level of evidence assigned as 3 (systematic review of heterogeneous, mostly observational studies); no meta-analysis was conducted due to methodological heterogeneity.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"warning","value":"Sex tag set to 'female' as the primary dataset covers maternal exposure; paternal exposure studies also exist but are a small subset (3 studies, 281 pregnancies).","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"warning","value":"The review included all indications for IL inhibitors (not psoriasis-only), so findings may not be fully generalizable to psoriasis patients specifically.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"warning","value":"The sample size (n=5,962) reflects maternal pregnancy exposures across all included studies, not a single trial cohort; the majority originated from pharmacovigilance databases with inherent reporting bias.","value_numeric":null}],"summaries":{"what_studied":"A PRISMA-compliant systematic literature review (search date May 2026) evaluated the reproductive safety of IL-12/23, IL-17, and IL-23 inhibitors during pregnancy and with paternal exposure in patients with psoriasis, examining pregnancy and neonatal outcomes across all available study designs.","key_result":"49 publications met inclusion criteria, reporting 5,962 pregnancies with maternal exposure; ustekinumab had the most data (2,933 pregnancies), followed by secukinumab (1,877), risankizumab (589), ixekizumab (296), guselkumab (217), tildrakizumab (32), bimekizumab (11), brodalumab (6), and mirikizumab (1). Cohort-level findings were generally reassuring — no consistent signal for adverse pregnancy or neonatal outcomes — except one study reporting increased risk of small-for-gestational-age infants with ustekinumab. Paternal exposure data were very limited (3 studies, 281 pregnancies).","limitations":"- Most exposures (n=5,074) came from pharmacovigilance databases that capture only adverse events, making incidence rates incalculable and meta-analysis infeasible.\n- Critical confounders (disease activity, exposure timing, comedications) were missing or unreported in the majority of studies; only one study used confounder-adjusted analysis.\n- Data were heavily skewed toward IBD patients, limiting psoriasis-specific and IL-17-specific conclusions.","practice_takeaway":"Available data are broadly reassuring but insufficient to issue definitive safety guidance; clinicians should weigh uncontrolled disease risk against medication uncertainty on a case-by-case basis. Existing psoriasis registries (e.g., BADBIR, BioCAPTURE) should add standardized pregnancy datasets to accelerate evidence generation."}},{"doi":"10.2340/actadv.v106.adv-2026-0490","pmid":"42708647","title":"The Efficacy of Different Treatment Options in Cutaneous Sarcoidosis: A Meta-analysis of RCTs","journal_title":"Acta Dermato-Venereologica","journal_issn":"1651-2057","published_at":"2026-09-08T00:00:00.000Z","url":"https://doi.org/10.2340/actadv.v106.adv-2026-0490","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-12T06:20:16.284Z","updated_at":"2026-09-12T06:20:16.284Z","tags":[{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"brand","value":"Humira","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"brand","value":"Rapamune","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"brand","value":"Remicade","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"brand","value":"Simponi","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"brand","value":"Stelara","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"condition","value":"Cutaneous Sarcoidosis","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"generic","value":"adalimumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"generic","value":"golimumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"generic","value":"infliximab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"generic","value":"sirolimus","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"generic","value":"thalidomide","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"generic","value":"ustekinumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"modality","value":"Antimycobacterial Combination Therapy","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"modality","value":"IL-12/23 Inhibitor","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"modality","value":"Immunomodulatory Agent","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"modality","value":"mTOR Inhibitor","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"modality","value":"TNF-alpha Inhibitor","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"sample_size","value":"n=156","value_numeric":156},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"study_design","value":"Systematic Review and Meta-analysis","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"warning","value":"Only 6 RCTs with 156 participants were pooled; the meta-analysis is substantially underpowered and results should be interpreted with caution.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"warning","value":"Publication bias could not be formally assessed due to the small number of included studies.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"warning","value":"Race and ethnicity data were inconsistently reported across trials, preventing subgroup analyses by demographic factors.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"warning","value":"The Judson 2014 trial included both golimumab and ustekinumab arms with a shared placebo group; the authors split the placebo arm proportionally to avoid unit-of-analysis errors, which introduces analytical uncertainty.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0490","tag_type":"warning","value":"The level of evidence tag '1' reflects the meta-analysis of RCTs study design, but GRADE certainty was rated 'very low' due to risk of bias, imprecision, and heterogeneity — the clinical confidence in the pooled estimates is therefore much lower than the design hierarchy alone implies.","value_numeric":null}],"summaries":{"what_studied":"This systematic review and meta-analysis of 6 double-blind, placebo-controlled RCTs (n=156 adults) evaluated the efficacy and safety of pharmacological add-on therapies — including infliximab, adalimumab, golimumab, ustekinumab, thalidomide, sirolimus (topical mTOR inhibitor), and the CLEAR antimycobacterial regimen — for cutaneous sarcoidosis, with all trials permitting concomitant corticosteroids.","key_result":"No pharmacological therapy significantly improved clinical response over placebo (OR 2.24; 95% CI 0.73–6.90; p=0.16). A non-significant trend toward better quality of life was seen (OR 2.23; 95% CI 0.87–5.73; p=0.09). Serious adverse events were similar between groups (OR 0.97; 95% CI 0.48–1.96; p=0.93). Overall certainty of evidence was very low (GRADE).","limitations":"- Only 6 RCTs with 156 total participants; severely underpowered for definitive conclusions.\n- Risk of bias was moderate-to-high in 4 of 6 studies, mainly due to missing outcome data and inadequate allocation concealment.\n- All trials allowed concurrent corticosteroids without standardized dosing or tapering, which may have blunted detection of treatment benefit. Publication bias could not be assessed.","practice_takeaway":"Current RCT evidence does not support a statistically significant benefit of steroid-sparing add-on therapies for cutaneous sarcoidosis; individualize treatment based on disease severity, comorbidities, and patient preferences. Emerging agents (JAK inhibitors, mTOR inhibitors) show promise in case reports but lack controlled trial data — do not use as standard care yet."}},{"doi":"10.1007/s10620-026-10231-1","pmid":"42704580","title":"IBD Nurse-Led Clinical Pathways to Optimize Patient Safety in Advanced Therapies: A Narrative Review","journal_title":"Digestive Diseases and Sciences","journal_issn":"0163-2116","published_at":"2026-09-07T00:00:00.000Z","url":"https://doi.org/10.1007/s10620-026-10231-1","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-15T06:17:42.129Z","updated_at":"2026-09-15T06:17:42.129Z","tags":[{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"condition","value":"Crohn's Disease","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"condition","value":"Inflammatory Bowel Disease","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"condition","value":"Ulcerative Colitis","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"adalimumab","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"azathioprine","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"etrasimod","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"filgotinib","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"golimumab","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"guselkumab","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"infliximab","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"mirikizumab","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"obefazimod","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"ozanimod","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"risankizumab","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"tofacitinib","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"upadacitinib","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"ustekinumab","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"generic","value":"vedolizumab","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"modality","value":"Anti-Integrin","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"modality","value":"Anti-TNF Agent","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"modality","value":"IL-12/23 Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"modality","value":"JAK Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"modality","value":"S1P Receptor Modulator","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"warning","value":"Evidence maturity varies considerably across domains: infection screening and infusion safety are well-supported, while remote monitoring and small-molecule nursing roles rest on a more heterogeneous evidence base.","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"warning","value":"No sample size applies — this is a narrative review synthesizing existing literature, not a primary study with enrolled participants.","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"warning","value":"Sex of study populations is not reported, as this review aggregates evidence across multiple heterogeneous sources.","value_numeric":null},{"paper_doi":"10.1007/s10620-026-10231-1","tag_type":"warning","value":"The seven nursing domains represent an interpretative synthesis, not a validated clinical framework; they have not undergone formal consensus, feasibility testing, or outcome evaluation.","value_numeric":null}],"summaries":{"what_studied":"This narrative review synthesized clinical, organizational, and nursing evidence on the role of specialist IBD nurses in managing biologic and small-molecule therapies, drawing on ECCO, BSG, and ACG guidelines plus literature up to December 2025 (with an August 2026 update).","key_result":"Seven interrelated nursing practice domains were identified: pretreatment assessment, therapy preparation, IV infusion management, self-administered therapy management, clinical and laboratory monitoring, critical event management, and core knowledge of biologic/small-molecule therapies. An eighth complementary section covers emerging therapies and special contexts (pregnancy, perianal disease, travel, pediatric/adolescent transition).","limitations":"- Narrative design lacks the exhaustiveness, reproducibility, and formal evidence appraisal of a systematic review; relevant sources may have been missed.\n- Included literature is highly heterogeneous (guidelines, observational studies, service reports, digital-health evaluations), limiting comparative conclusions about individual pathway components.\n- No formal framework-development process was conducted (no expert consensus, stakeholder validation, feasibility testing, or implementation evaluation), so the thematic domains should not be treated as a validated clinical framework or standard of care.","practice_takeaway":"IBD nurses should follow structured, protocol-driven pathways across all phases of advanced therapy—from infectious screening and pharmacogenetic testing before initiation, to predefined escalation algorithms for infusion reactions, infections, VTE, and cardiovascular events. Centers developing or expanding IBD nursing services can use the seven domains as an evidence-informed starting point, while recognizing that formal validation and local adaptation are still needed."}},{"doi":"10.1016/j.cgh.2026.08.014","pmid":"42660257","title":"Clinical Outcomes After Ustekinumab Biosimilar Switching in Crohn’s Disease: the USBIOS IG-IBD Study","journal_title":"Clinical Gastroenterology and Hepatology","journal_issn":"1542-3565","published_at":"2026-08-27T00:00:00.000Z","url":"https://doi.org/10.1016/j.cgh.2026.08.014","source_score":10,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-01T06:21:08.279Z","updated_at":"2026-09-01T06:21:08.279Z","tags":[{"paper_doi":"10.1016/j.cgh.2026.08.014","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.08.014","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.08.014","tag_type":"condition","value":"Crohn's Disease","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.08.014","tag_type":"generic","value":"ustekinumab","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.08.014","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.08.014","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.08.014","tag_type":"modality","value":"IL-12/23 Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.08.014","tag_type":"sample_size","value":"n=462","value_numeric":462},{"paper_doi":"10.1016/j.cgh.2026.08.014","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.08.014","tag_type":"study_design","value":"Prospective Observational Cohort Study","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.08.014","tag_type":"warning","value":"Brand names of the 3 specific biosimilars used are not listed in the abstract; brand/generic tags for individual biosimilars could not be added.","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.08.014","tag_type":"warning","value":"Every-4-week dosing subgroup is very small (n=4, 0.9%), limiting any subgroup inference for that population.","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.08.014","tag_type":"warning","value":"The control group (n=125) was not randomly assigned; procurement-driven allocation may introduce unmeasured confounding despite propensity-score adjustment.","value_numeric":null}],"summaries":{"what_studied":"This prospective observational cohort study at 18 Italian centers compared 6-month clinical outcomes in adults with Crohn's disease (CD) in stable remission who underwent a procurement-driven nonmedical switch from reference ustekinumab to one of 3 approved biosimilars (n=337) versus those who continued reference treatment (n=125).","key_result":"Expanded clinical success (remission, steroid-free, no biologic discontinuation, no IBD hospitalization or surgery) was achieved in 92.2% of switchers vs. 92.7% of controls (risk difference −0.5%, 95% CI −5.9 to 4.9), meeting the prespecified noninferiority margin of −15%. Biosimilar persistence was 93.7%; switch-back rate was 1.2%; only 2 adverse events were reported after switching.","limitations":"- Observational design with unequal group sizes (337 vs. 125) and potential selection bias, despite propensity-score weighting.\n- Only 4 patients (0.9%) were on every-4-week dosing, so results may not generalize to this higher-intensity subgroup.\n- Follow-up was limited to 6 months; longer-term durability of biosimilar switching remains unknown.","practice_takeaway":"For clinically stable CD patients on reference ustekinumab, a nonmedical switch to an approved biosimilar appears safe and effective over 6 months, with outcomes virtually identical to staying on the reference product. Clinicians can proceed with procurement-driven switches in this population but should monitor patients on every-4-week dosing more closely, as evidence is very limited for that group."}},{"doi":"10.14309/ajg.0000000000004119","pmid":"42467952","title":"Absolute Risk of Malignancy by Treatment in Patients With Crohn's Disease Compared with the General Population: A Nationwide Population-Based Cohort Study","journal_title":"American Journal of Gastroenterology","journal_issn":"0002-9270","published_at":"2026-08-26T00:00:00.000Z","url":"https://doi.org/10.14309/ajg.0000000000004119","source_score":14,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-28T06:25:32.491Z","updated_at":"2026-08-28T06:25:32.491Z","tags":[{"paper_doi":"10.14309/ajg.0000000000004119","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.14309/ajg.0000000000004119","tag_type":"brand","value":"Entyvio","value_numeric":null},{"paper_doi":"10.14309/ajg.0000000000004119","tag_type":"brand","value":"Stelara","value_numeric":null},{"paper_doi":"10.14309/ajg.0000000000004119","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.14309/ajg.0000000000004119","tag_type":"condition","value":"Crohn's Disease","value_numeric":null},{"paper_doi":"10.14309/ajg.0000000000004119","tag_type":"condition","value":"Malignancy","value_numeric":null},{"paper_doi":"10.14309/ajg.0000000000004119","tag_type":"condition","value":"Nonmelanoma Skin Cancer","value_numeric":null},{"paper_doi":"10.14309/ajg.0000000000004119","tag_type":"generic","value":"azathioprine","value_numeric":null},{"paper_doi":"10.14309/ajg.0000000000004119","tag_type":"generic","value":"ustekinumab","value_numeric":null},{"paper_doi":"10.14309/ajg.0000000000004119","tag_type":"generic","value":"vedolizumab","value_numeric":null},{"paper_doi":"10.14309/ajg.0000000000004119","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.14309/ajg.0000000000004119","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.14309/ajg.0000000000004119","tag_type":"modality","value":"IL-12/23 Inhibitor","value_numeric":null},{"paper_doi":"10.14309/ajg.0000000000004119","tag_type":"modality","value":"Integrin Inhibitor","value_numeric":null},{"paper_doi":"10.14309/ajg.0000000000004119","tag_type":"modality","value":"Thiopurine","value_numeric":null},{"paper_doi":"10.14309/ajg.0000000000004119","tag_type":"modality","value":"TNF Inhibitor","value_numeric":null},{"paper_doi":"10.14309/ajg.0000000000004119","tag_type":"sample_size","value":"n=38733","value_numeric":38733},{"paper_doi":"10.14309/ajg.0000000000004119","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.14309/ajg.0000000000004119","tag_type":"study_design","value":"Population-Based Cohort Study","value_numeric":null},{"paper_doi":"10.14309/ajg.0000000000004119","tag_type":"warning","value":"Comparator group (n=360,616) is substantially larger than the patient cohort; matching details and ratio are not fully described in the abstract.","value_numeric":null},{"paper_doi":"10.14309/ajg.0000000000004119","tag_type":"warning","value":"Impact flag 'practice_changing' applied cautiously — findings reinforce skin cancer surveillance across all CD patients and may influence biologic selection, but vedolizumab/ustekinumab results are underpowered.","value_numeric":null},{"paper_doi":"10.14309/ajg.0000000000004119","tag_type":"warning","value":"The 'once-exposed-always-exposed' design means patients are kept in a treatment cohort regardless of stopping or switching therapy, which may overestimate or distort treatment-specific cancer risk.","value_numeric":null},{"paper_doi":"10.14309/ajg.0000000000004119","tag_type":"warning","value":"The thiopurine generic tag uses azathioprine as a representative agent; the paper refers broadly to thiopurines, which may also include mercaptopurine or thioguanine.","value_numeric":null}],"summaries":{"what_studied":"This nationwide Swedish register-based cohort study assessed absolute cancer risk in 38,733 patients with Crohn's disease (CD) across six treatment cohorts (thiopurine, TNFi, thiopurine+TNFi, vedolizumab, ustekinumab, and immunomodulator-naïve) versus 360,616 matched general-population comparators, followed for a median of 7.3 years (2007–2023).","key_result":"Excess cancer incidence (vs. general population) ranged from 1.54 to 3.14 per 1,000 person-years across all treatment groups, including naïve patients (2.43; 95% CI 1.92–2.94); nonmelanoma skin cancer drove most of the excess. After excluding nonmelanoma skin cancers, excess incidence fell to ~1 extra case per 1,000 person-years in naïve, thiopurine, and TNFi cohorts (driven by lung, small bowel, hepatobiliary, and hematologic cancers), and was not significantly elevated in vedolizumab or ustekinumab groups.","limitations":"- Once-exposed-always-exposed design may not capture treatment duration or switching effects accurately.\n- Residual confounding by disease severity and indication bias cannot be excluded, as sicker patients are more likely to receive immunomodulators.\n- Ustekinumab and vedolizumab cohorts had wide confidence intervals, suggesting limited statistical power for those groups.","practice_takeaway":"All CD patients—even those on no immunomodulatory therapy—carry a modestly elevated cancer risk vs. the general population, largely from nonmelanoma skin cancer; counsel patients across all treatment lines about skin surveillance. After excluding skin cancers, vedolizumab and ustekinumab users did not show a statistically significant excess cancer risk, which may be reassuring when choosing therapy for higher-risk patients."}},{"doi":"10.1002/art.70297","pmid":"42605840","title":"Risk of Cancer according to Duration of Targeted Therapy Exposure in Spondyloarthritis: A Nationwide Cohort Study from the French Health Insurance Database","journal_title":"Arthritis & Rheumatology","journal_issn":"2326-5191","published_at":"2026-08-17T00:00:00.000Z","url":"https://doi.org/10.1002/art.70297","source_score":3,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-22T06:53:21.288Z","updated_at":"2026-08-22T06:53:21.288Z","tags":[{"paper_doi":"10.1002/art.70297","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1002/art.70297","tag_type":"category","value":"Rheumatology","value_numeric":null},{"paper_doi":"10.1002/art.70297","tag_type":"condition","value":"Axial Spondyloarthritis","value_numeric":null},{"paper_doi":"10.1002/art.70297","tag_type":"condition","value":"Cancer","value_numeric":null},{"paper_doi":"10.1002/art.70297","tag_type":"condition","value":"Psoriatic Arthritis","value_numeric":null},{"paper_doi":"10.1002/art.70297","tag_type":"condition","value":"Spondyloarthritis","value_numeric":null},{"paper_doi":"10.1002/art.70297","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1002/art.70297","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1002/art.70297","tag_type":"modality","value":"IL-12/23 Inhibitor","value_numeric":null},{"paper_doi":"10.1002/art.70297","tag_type":"modality","value":"IL-17 Inhibitor","value_numeric":null},{"paper_doi":"10.1002/art.70297","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.1002/art.70297","tag_type":"modality","value":"JAK Inhibitor","value_numeric":null},{"paper_doi":"10.1002/art.70297","tag_type":"modality","value":"TNF Inhibitor","value_numeric":null},{"paper_doi":"10.1002/art.70297","tag_type":"sample_size","value":"n=56591","value_numeric":56591},{"paper_doi":"10.1002/art.70297","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1002/art.70297","tag_type":"study_design","value":"Nationwide Cohort Study","value_numeric":null},{"paper_doi":"10.1002/art.70297","tag_type":"warning","value":"Causal inference relies on inverse probability weighting from claims data; unmeasured confounders (e.g., disease severity, concomitant medications) may not be fully accounted for.","value_numeric":null},{"paper_doi":"10.1002/art.70297","tag_type":"warning","value":"The protective signal for hematological malignancies (wHR 0.65) is based on only 116 events, so this estimate should be interpreted cautiously — wide confidence intervals reflect limited precision.","value_numeric":null},{"paper_doi":"10.1002/art.70297","tag_type":"warning","value":"The study pools multiple SpA subtypes and multiple drug classes (TNFi, IL-17i, IL-12/23i, IL-23i, JAKi) into a single exposure variable; drug-class-specific or subtype-specific cancer risks may differ and are not fully delineated in the abstract.","value_numeric":null}],"summaries":{"what_studied":"This nationwide French cohort study examined whether duration of targeted therapy exposure (TNFi, IL-17i, IL-12/23i, IL-23i, JAKi) affects cancer risk in 56,591 adults with spondyloarthritis (including psoriatic arthritis and axial SpA), followed for a median of 5.0 years (2014–2024).","key_result":"Exposure >6 months/year vs. ≤6 months/year was associated with a **lower** overall cancer risk (wHR 0.86, 95% CI 0.75–0.99), driven primarily by hematological malignancies (wHR 0.65, 95% CI 0.42–0.99); no significant reduction was seen for solid cancers (wHR 0.92, 95% CI 0.79–1.07). Of 1,224 total cancers, 1,029 were solid and 116 hematological. Cumulative multi-year exposure was not associated with cancer risk.","limitations":"- **Observational design**: residual confounding cannot be excluded despite inverse probability weighting.\n- **Database-based exposure**: therapy adherence is inferred from insurance claims, not directly measured.\n- **Heterogeneous SpA subtypes**: pooling psoriatic arthritis, axial SpA, and other subtypes may obscure subgroup-specific risks.","practice_takeaway":"Clinicians can reassure patients with SpA that prolonged targeted therapy use is not associated with increased cancer risk — and may even lower hematological malignancy risk. Cumulative years of exposure should not, on its own, prompt treatment discontinuation over cancer concerns."}},{"doi":"10.1016/j.cgh.2026.07.020","pmid":"42562116","title":"Superior Effectiveness of Upadacitinib Over Tofacitinib and Ustekinumab in Bio-Exposed Ulcerative Colitis: The TRIDENT-UC Study","journal_title":"Clinical Gastroenterology and Hepatology","journal_issn":"1542-3565","published_at":"2026-08-07T00:00:00.000Z","url":"https://doi.org/10.1016/j.cgh.2026.07.020","source_score":7,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-14T13:24:53.592Z","updated_at":"2026-08-14T13:24:53.592Z","tags":[{"paper_doi":"10.1016/j.cgh.2026.07.020","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.07.020","tag_type":"brand","value":"Rinvoq","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.07.020","tag_type":"brand","value":"Stelara","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.07.020","tag_type":"brand","value":"Xeljanz","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.07.020","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.07.020","tag_type":"condition","value":"Ulcerative Colitis","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.07.020","tag_type":"generic","value":"tofacitinib","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.07.020","tag_type":"generic","value":"upadacitinib","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.07.020","tag_type":"generic","value":"ustekinumab","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.07.020","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.07.020","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.07.020","tag_type":"modality","value":"IL-12/23 Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.07.020","tag_type":"modality","value":"JAK Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.07.020","tag_type":"sample_size","value":"n=312","value_numeric":312},{"paper_doi":"10.1016/j.cgh.2026.07.020","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.07.020","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.07.020","tag_type":"warning","value":"The mean age at diagnosis (32.6 years) is reported, but the age range of enrolled patients is not provided, limiting age-group precision beyond 'adult'.","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.07.020","tag_type":"warning","value":"The 'practice_changing' impact flag is applied cautiously — this is a retrospective observational study with IPTW adjustment, not a head-to-head RCT; residual confounding cannot be excluded.","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.07.020","tag_type":"warning","value":"Tofacitinib subgroup (n=74) is notably smaller than ustekinumab (n=135) and upadacitinib (n=103), which may affect the stability of IPTW-weighted estimates for that arm.","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.07.020","tag_type":"warning","value":"Ustekinumab is not FDA-approved specifically for UC in the same manner as for Crohn's disease; its use in this context may reflect off-label or region-specific prescribing practices.","value_numeric":null}],"summaries":{"what_studied":"Retrospective multicenter study (9 centers, n=312) comparing upadacitinib, tofacitinib, and ustekinumab in bio-exposed UC patients who had failed ≥1 advanced therapy, assessed at weeks 16 and 52 for steroid-free clinical remission (SFCR) and endoscopic remission.","key_result":"After propensity score-weighted analysis, upadacitinib had higher SFCR odds vs. tofacitinib (w16: OR 2.56; w52: OR 3.14) and ustekinumab (w16: OR 3.71; w52: OR 4.68). Endoscopic remission rates at w52 were 56.8% (upadacitinib) vs. 32.7% (tofacitinib) vs. 22.5% (ustekinumab), with upadacitinib outperforming both at both timepoints.","limitations":"Retrospective design with inherent selection bias; IPTW mitigates but does not eliminate confounding; single-country or limited-center generalizability not specified, and small subgroup sizes (tofacitinib n=74) may limit precision of estimates.","practice_takeaway":"In UC patients who have failed a prior biologic, upadacitinib achieves meaningfully higher rates of steroid-free clinical and endoscopic remission than either tofacitinib or ustekinumab at both 16 and 52 weeks. Clinicians should prioritize upadacitinib when selecting a second-line advanced therapy in this population."}},{"doi":"10.1093/ibd/izag142","pmid":"42520305","title":"Risk of serious infection, myocardial infarction, stroke, and thromboembolic events in patients in the United States with ulcerative colitis treated with tofacitinib compared with biologic treatments","journal_title":"Inflammatory Bowel Diseases","journal_issn":"1078-0998","published_at":"2026-07-28T00:00:00.000Z","url":"https://doi.org/10.1093/ibd/izag142","source_score":7,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-04T18:18:01.291Z","updated_at":"2026-08-04T18:18:01.291Z","tags":[{"paper_doi":"10.1093/ibd/izag142","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1093/ibd/izag142","tag_type":"brand","value":"Entyvio","value_numeric":null},{"paper_doi":"10.1093/ibd/izag142","tag_type":"brand","value":"Stelara","value_numeric":null},{"paper_doi":"10.1093/ibd/izag142","tag_type":"brand","value":"Xeljanz","value_numeric":null},{"paper_doi":"10.1093/ibd/izag142","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1093/ibd/izag142","tag_type":"condition","value":"Ulcerative Colitis","value_numeric":null},{"paper_doi":"10.1093/ibd/izag142","tag_type":"generic","value":"tofacitinib","value_numeric":null},{"paper_doi":"10.1093/ibd/izag142","tag_type":"generic","value":"ustekinumab","value_numeric":null},{"paper_doi":"10.1093/ibd/izag142","tag_type":"generic","value":"vedolizumab","value_numeric":null},{"paper_doi":"10.1093/ibd/izag142","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1093/ibd/izag142","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1093/ibd/izag142","tag_type":"modality","value":"IL-12/23 Inhibitor","value_numeric":null},{"paper_doi":"10.1093/ibd/izag142","tag_type":"modality","value":"Integrin Inhibitor","value_numeric":null},{"paper_doi":"10.1093/ibd/izag142","tag_type":"modality","value":"JAK Inhibitor","value_numeric":null},{"paper_doi":"10.1093/ibd/izag142","tag_type":"modality","value":"TNF Inhibitor","value_numeric":null},{"paper_doi":"10.1093/ibd/izag142","tag_type":"sample_size","value":"n=62596","value_numeric":62596},{"paper_doi":"10.1093/ibd/izag142","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1093/ibd/izag142","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1093/ibd/izag142","tag_type":"warning","value":"Sample size is the sum of all four treatment groups (5171 + 10424 + 17129 + 29872 = 62596); individual group Ns vary considerably, which may affect power for rare outcomes like MI/stroke.","value_numeric":null},{"paper_doi":"10.1093/ibd/izag142","tag_type":"warning","value":"TNF inhibitor brand names were not individually specified in the abstract; no brand tags were added for this class.","value_numeric":null},{"paper_doi":"10.1093/ibd/izag142","tag_type":"warning","value":"Tofacitinib initiators were markedly more biologic-experienced than biologic initiators at baseline; sIPTW adjustment was applied but residual confounding by indication is likely. Interpret hazard ratios with caution.","value_numeric":null}],"summaries":{"what_studied":"This retrospective cohort study used US claims data (Komodo Health) to compare risks of serious infection, MI, stroke, and VTE among UC patients initiating tofacitinib, ustekinumab, vedolizumab, or TNF inhibitors between May 2018 and September 2022, with a mean follow-up of ~359 days.","key_result":"No significant risk differences were found between tofacitinib and any biologic. Serious infection IRs/100 PY were 2.62 (tofacitinib), 2.73 (ustekinumab), 2.45 (vedolizumab), and 3.25 (TNFi). MI/stroke IRs/100 PY were 0.13, 0.17, 0.17, and 0.19; VTE IRs/100 PY were 0.17, 0.16, 0.23, and 0.33, respectively.","limitations":"- Tofacitinib initiators were more biologic-experienced at baseline (46.3% had ≥2 prior biologics vs 7.5%–33.7% for biologics), indicating channeling bias that sIPTW adjustment may not fully correct.\n- Mean follow-up of ~359 days may miss long-term safety signals.\n- Claims data cannot capture unmeasured confounders (e.g., disease severity, smoking status).","practice_takeaway":"In a large US real-world population with UC, tofacitinib showed no significantly higher risk of serious infection, MI, stroke, or VTE compared with ustekinumab, vedolizumab, or TNF inhibitors. Clinicians can factor these data into shared decision-making, particularly for biologic-experienced patients weighing tofacitinib."}},{"doi":"10.1001/jamadermatol.2026.2365","pmid":"42455533","title":"Tuberculosis-Related Outcomes in Dermatologic Patients Receiving Systemic Therapy","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2026-07-15T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2026.2365","source_score":16,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-21T23:14:01.883Z","updated_at":"2026-09-21T23:14:01.883Z","tags":[{"paper_doi":"10.1001/jamadermatol.2026.2365","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2365","tag_type":"brand","value":"Stelara","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2365","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2365","tag_type":"condition","value":"Latent Tuberculosis Infection","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2365","tag_type":"condition","value":"Psoriasis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2365","tag_type":"condition","value":"Systemic Lupus Erythematosus","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2365","tag_type":"condition","value":"Systemic Sclerosis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2365","tag_type":"condition","value":"Tuberculosis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2365","tag_type":"generic","value":"adalimumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2365","tag_type":"generic","value":"belimumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2365","tag_type":"generic","value":"etanercept","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2365","tag_type":"generic","value":"infliximab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2365","tag_type":"generic","value":"ixekizumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2365","tag_type":"generic","value":"rituximab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2365","tag_type":"generic","value":"secukinumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2365","tag_type":"generic","value":"ustekinumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2365","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2365","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2365","tag_type":"modality","value":"Conventional Immunosuppressant","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2365","tag_type":"modality","value":"Glucocorticoid","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2365","tag_type":"modality","value":"IL-12/23 Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2365","tag_type":"modality","value":"IL-17 Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2365","tag_type":"modality","value":"TNF Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2365","tag_type":"sample_size","value":"n=15005","value_numeric":15005},{"paper_doi":"10.1001/jamadermatol.2026.2365","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2365","tag_type":"study_design","value":"Systematic Review and Meta-Analysis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2365","tag_type":"warning","value":"Active TB rates varied dramatically across individual studies (0.095% to 30.2%), largely driven by regional TB burden and immunosuppressive regimen intensity—pooled estimates should be interpreted in the context of local epidemiology.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2365","tag_type":"warning","value":"IL-23 inhibitors (as a separate class from IL-12/23) were present in some included studies but were grouped under IL-12/23 for some analyses; mechanism-specific estimates for IL-23 monotherapy may not be fully separable.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2365","tag_type":"warning","value":"Substantial heterogeneity (I² = 81%) in biologic LTBI conversion analyses limits the reliability of pooled figures across biologic classes.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.2365","tag_type":"warning","value":"The paper is a supplemental online content document; forest plot numeric values are described but not fully reproduced in text, so exact subgroup incidence rates by biologic class are not extractable from this source.","value_numeric":null}],"summaries":{"what_studied":"This systematic review and meta-analysis evaluated the incidence of active TB and LTBI conversion in dermatologic patients receiving systemic therapy (biologics, glucocorticoids, conventional immunosuppressants), spanning 31 studies with 15,005 patients searched through October 2025, with subgroup analyses by biologic class (TNF inhibitors, IL-17, IL-12/23) and regional TB burden.","key_result":"Pooled LTBI conversion rate was 4.3% overall, highest with TNF inhibitors, followed by IL-17 inhibitors and ustekinumab (IL-12/23 p40 inhibitor). Active TB incidence was 1.0% overall, with markedly higher rates in high-burden regions (e.g., 30.2% in India with high-dose glucocorticoids, 14.1% in South Africa with SLE) versus very low rates in low-burden regions (e.g., 0.095% in the UK). Biologic-only LTBI conversion analyses showed substantial heterogeneity (I² = 81%).","limitations":"High heterogeneity across studies (I² = 81% for biologic LTBI conversion) limits precision of pooled estimates. LTBI testing methods varied (TST vs. IGRA) and baseline screening protocols differed. Most included studies were observational cohorts with variable prophylaxis use, follow-up duration, and risk-of-bias scores (NOS 4–8/9).","practice_takeaway":"Screen all dermatologic patients for LTBI before starting biologics—especially TNF inhibitors—and factor in regional TB burden when deciding on prophylaxis and monitoring intensity. In high-burden regions, even conventional immunosuppressants (glucocorticoids) carry substantial active TB risk and warrant close vigilance."}},{"doi":"10.1016/j.ard.2026.06.017","pmid":"42431784","title":"Cancer risk of Janus kinase inhibitors and other advanced therapies in immune-mediated inflammatory diseases: a systematic review and Bayesian network meta-analysis of RCTs","journal_title":"Annals of the Rheumatic Diseases","journal_issn":"0003-4967","published_at":"2026-07-10T00:00:00.000Z","url":"https://doi.org/10.1016/j.ard.2026.06.017","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-23T13:33:19.238Z","updated_at":"2026-07-23T13:33:19.238Z","tags":[{"paper_doi":"10.1016/j.ard.2026.06.017","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.ard.2026.06.017","tag_type":"category","value":"Rheumatology","value_numeric":null},{"paper_doi":"10.1016/j.ard.2026.06.017","tag_type":"condition","value":"Inflammatory Bowel Disease","value_numeric":null},{"paper_doi":"10.1016/j.ard.2026.06.017","tag_type":"condition","value":"Psoriasis","value_numeric":null},{"paper_doi":"10.1016/j.ard.2026.06.017","tag_type":"condition","value":"Psoriatic Arthritis","value_numeric":null},{"paper_doi":"10.1016/j.ard.2026.06.017","tag_type":"condition","value":"Rheumatoid Arthritis","value_numeric":null},{"paper_doi":"10.1016/j.ard.2026.06.017","tag_type":"generic","value":"tofacitinib","value_numeric":null},{"paper_doi":"10.1016/j.ard.2026.06.017","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.ard.2026.06.017","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1016/j.ard.2026.06.017","tag_type":"modality","value":"CD20 Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.ard.2026.06.017","tag_type":"modality","value":"CTLA-4 Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.ard.2026.06.017","tag_type":"modality","value":"IL-12/23 Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.ard.2026.06.017","tag_type":"modality","value":"IL-17 Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.ard.2026.06.017","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.ard.2026.06.017","tag_type":"modality","value":"IL-6 Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.ard.2026.06.017","tag_type":"modality","value":"JAK Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.ard.2026.06.017","tag_type":"modality","value":"TNF Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.ard.2026.06.017","tag_type":"sample_size","value":"n=164824","value_numeric":164824},{"paper_doi":"10.1016/j.ard.2026.06.017","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.ard.2026.06.017","tag_type":"study_design","value":"Systematic Review and Network Meta-Analysis","value_numeric":null},{"paper_doi":"10.1016/j.ard.2026.06.017","tag_type":"warning","value":"Class-level pooling of JAK inhibitors may mask agent-specific or dose-specific differences; individual drug comparisons are not reported.","value_numeric":null},{"paper_doi":"10.1016/j.ard.2026.06.017","tag_type":"warning","value":"Long-term extension studies are included alongside RCTs, which may introduce exposure-time bias favoring detection of malignancy in longer studies.","value_numeric":null},{"paper_doi":"10.1016/j.ard.2026.06.017","tag_type":"warning","value":"The absolute risk calculations depend on assumed baseline cancer incidence rates for 'standard-risk' vs 'higher-risk' populations, which are not fully specified in the abstract—clinicians should interpret absolute numbers cautiously without the full paper.","value_numeric":null}],"summaries":{"what_studied":"This systematic review and Bayesian network meta-analysis evaluated relative and absolute cancer risk of JAK inhibitors (JAKis) vs other advanced therapies (TNFi, IL-6, IL-17, IL-23, IL-12/23, CTLA-4, CD20 inhibitors) across immune-mediated inflammatory diseases (RA, PsO/PsA, IBD) using 305 RCTs and long-term extension studies (164,824 participants; 264,100 person-years exposure) published up to February 2026.","key_result":"JAKis were associated with higher malignancy risk than TNFi (RR 1.60; 95% CrI 1.27–2.02) and standard care (RR 1.85; 95% CrI 1.38–2.47) across all three disease areas. Absolute excess risk vs TNFi was negligible in standard-risk patients (~1 extra cancer per 27,000 person-years) but clinically meaningful in high-risk patients (~1 extra cancer per 147 person-years). IL-6, IL-17, IL-23, IL-12/23, CTLA-4, and CD20 inhibitors showed cancer risks broadly comparable to TNFi.","limitations":"- Relies on RCT and long-term extension data, which may underrepresent older or higher-risk patients seen in routine care.\n- Class-level pooling may obscure differences between individual JAKi agents or doses.\n- Malignancy outcomes (including non-melanoma skin cancer) vary in ascertainment and reporting across trials.","practice_takeaway":"Clinicians should apply risk-stratified decision-making when prescribing JAKis across all IMIDs—not just RA—particularly in patients with prior malignancy or other cancer risk factors. For standard-risk patients the absolute excess risk vs TNFi is very small, but it becomes meaningful in higher-risk populations (~1 extra cancer per 147 person-years)."}},{"doi":"10.1016/j.cgh.2026.06.003","pmid":"42269996","title":"Risk of lymphoma associated with biologics and immunosuppressants in inflammatory bowel disease patients: a nationwide nested case-control study","journal_title":"Clinical Gastroenterology and Hepatology","journal_issn":"1542-3565","published_at":"2026-06-11T00:00:00.000Z","url":"https://doi.org/10.1016/j.cgh.2026.06.003","source_score":7,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-17T13:29:46.577Z","updated_at":"2026-06-17T13:29:46.577Z","tags":[{"paper_doi":"10.1016/j.cgh.2026.06.003","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.06.003","tag_type":"brand","value":"Entyvio","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.06.003","tag_type":"brand","value":"Stelara","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.06.003","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.06.003","tag_type":"condition","value":"Crohn's Disease","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.06.003","tag_type":"condition","value":"Inflammatory Bowel Disease","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.06.003","tag_type":"condition","value":"Lymphoma","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.06.003","tag_type":"condition","value":"Ulcerative Colitis","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.06.003","tag_type":"generic","value":"azathioprine","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.06.003","tag_type":"generic","value":"methotrexate","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.06.003","tag_type":"generic","value":"ustekinumab","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.06.003","tag_type":"generic","value":"vedolizumab","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.06.003","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.06.003","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.06.003","tag_type":"modality","value":"IL-12/23 Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.06.003","tag_type":"modality","value":"Integrin Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.06.003","tag_type":"modality","value":"JAK Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.06.003","tag_type":"modality","value":"Thiopurine","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.06.003","tag_type":"modality","value":"TNF Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.06.003","tag_type":"sample_size","value":"n=422793","value_numeric":422793},{"paper_doi":"10.1016/j.cgh.2026.06.003","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.06.003","tag_type":"study_design","value":"Nested Case-Control Study","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.06.003","tag_type":"warning","value":"Crohn's disease and ulcerative colitis are not explicitly broken out as separate conditions in the abstract; they are inferred as the IBD subtypes studied.","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.06.003","tag_type":"warning","value":"JAK inhibitor exposure details (specific agents, duration) are not described in the abstract, limiting interpretation of the null finding for that class.","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.06.003","tag_type":"warning","value":"Methotrexate's lymphoma association was flagged as inconsistent across sensitivity analyses — tag for this drug should be interpreted with caution.","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.06.003","tag_type":"warning","value":"The paper's DOI and publication date (June 11, 2026) are in the future relative to standard indexing; content appears to be an advance publication — conclusions should be treated as preliminary until final peer-reviewed version is confirmed.","value_numeric":null}],"summaries":{"what_studied":"This nationwide nested case-control study evaluated lymphoma risk associated with IBD treatments — thiopurines, methotrexate, anti-TNF agents, vedolizumab, ustekinumab, and JAK inhibitors — in 422,793 IBD patients from the French National Health Data System (SNDS) between 2009 and 2024, with 1,238 lymphoma cases matched to 52,565 controls.","key_result":"Current thiopurine use nearly doubled lymphoma risk (aOR 2.36, 95% CI 2.00–2.79) and anti-TNF use raised it by 72% (aOR 1.72, 95% CI 1.45–2.05); their combination more than tripled risk (aOR 3.44, 95% CI 2.62–4.51). Vedolizumab, ustekinumab, and JAK inhibitors showed no increased lymphoma risk.","limitations":"Methotrexate's association with lymphoma was inconsistent across sensitivity analyses, limiting firm conclusions. As a claims-based study, residual confounding by disease severity or unmeasured factors cannot be excluded. Exposure to newer agents (vedolizumab, ustekinumab, JAKi) may be underrepresented, limiting power for those comparisons.","practice_takeaway":"When choosing maintenance therapy for IBD, clinicians should weigh the clear lymphoma risk of thiopurines and anti-TNF — especially in combination — against the reassuring safety profile of vedolizumab, ustekinumab, and JAK inhibitors. Elevated risk from thiopurines may persist up to 3 years after stopping, so post-discontinuation vigilance is warranted."}},{"doi":"10.1007/s13555-026-01761-7","pmid":"42068460","title":"A Narrative Review: Do Systemic Drugs Used in the Treatment of Psoriatic Disease Affect Alzheimer’s Disease?","journal_title":"Dermatology and Therapy","journal_issn":"2193-8210","published_at":"2026-05-02T00:00:00.000Z","url":"https://doi.org/10.1007/s13555-026-01761-7","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-10T13:20:36.620Z","updated_at":"2026-05-10T13:20:36.620Z","tags":[{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"brand","value":"Cosentyx","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"brand","value":"Enbrel","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"brand","value":"Humira","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"brand","value":"Otezla","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"brand","value":"Remicade","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"brand","value":"Sotyktu","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"brand","value":"Stelara","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"condition","value":"Alzheimer's Disease","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"condition","value":"Dementia","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"condition","value":"Psoriasis","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"condition","value":"Psoriatic Arthritis","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"acitretin","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"adalimumab","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"apremilast","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"cyclosporine","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"deucravacitinib","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"etanercept","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"infliximab","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"methotrexate","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"roflumilast","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"secukinumab","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"tofacitinib","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"upadacitinib","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"generic","value":"ustekinumab","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"modality","value":"Conventional Synthetic DMARD","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"modality","value":"IL-12/23 Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"modality","value":"IL-17 Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"modality","value":"JAK Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"modality","value":"NSAID","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"modality","value":"PDE4 Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"modality","value":"Retinoid","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"modality","value":"TNF-Alpha Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"modality","value":"TYK2 Inhibitor","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"warning","value":"Corresponding author (Tsen-Fang Tsai) has disclosed extensive consultant relationships with manufacturers of many drugs discussed in the review.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"warning","value":"Level of evidence assigned as 5 (narrative review/expert opinion) due to absence of PRISMA methodology, risk-of-bias tools, or meta-analytic synthesis, even though individual cited studies range from Level 1 to Level 5.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"warning","value":"Several drug-AD associations cited are from studies in rheumatoid arthritis populations, not specifically psoriasis patients; generalizability to psoriatic disease may be limited.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01761-7","tag_type":"warning","value":"This is a narrative review without formal systematic methods; findings are hypothesis-generating and subject to selection bias in included studies.","value_numeric":null}],"summaries":{"what_studied":"This narrative review examined whether systemic drugs used for psoriatic disease (NSAIDs, methotrexate, cyclosporin, retinoids, PDE4 inhibitors, JAK inhibitors, TYK2 inhibitors, and biologics targeting TNF-α, IL-12/23, IL-17, and IL-23) influence the risk or progression of Alzheimer's disease (AD), using AD as a model for dementia. Literature from PubMed (2015–2025) was synthesized across preclinical, observational, and RCT-level evidence.","key_result":"Most preclinical and observational data suggest antipsoriatic therapies may reduce AD risk. The strongest clinical signal comes from a propensity score–matched cohort (n=1,766) showing biologic therapy for psoriasis was associated with a **53% lower risk of incident dementia** vs. conventional systemic therapy alone. In a large EHR-based study (56 million records), TNF inhibitors (etanercept, adalimumab, infliximab) were linked to markedly reduced AD odds (ORs 0.34, 0.28, and 0.52, respectively; all P<0.0001). However, several large observational studies found the psoriasis–dementia association attenuated or disappeared after adjusting for comorbidities.","limitations":"- Narrative (not systematic) review with no PRISMA flow, risk-of-bias assessment, or quantitative synthesis, limiting reproducibility.\n- Most mechanistic evidence comes from preclinical models (Level 5), with very few adequately powered RCTs in humans.\n- Residual confounding by disease severity, metabolic comorbidities, and medication use cannot be excluded in observational studies.","practice_takeaway":"For older patients with psoriasis, consider early cognitive screening, as shared inflammatory mechanisms may raise dementia risk—especially in those with metabolic comorbidities. Biologic therapy, particularly TNF inhibitors, shows the most consistent signal for possible neuroprotection, but current evidence is hypothesis-generating and should not yet change prescribing solely for dementia prevention."}},{"doi":"10.1016/j.cgh.2026.04.015","pmid":"42055304","title":"Serious infection in inflammatory bowel diseases patients treated with vedolizumab, ustekinumab, JAK inhibitors, anti-TNF or aminosalicylates","journal_title":"Clinical Gastroenterology and Hepatology","journal_issn":"1542-3565","published_at":"2026-04-27T00:00:00.000Z","url":"https://doi.org/10.1016/j.cgh.2026.04.015","source_score":10,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-09T13:22:18.216Z","updated_at":"2026-05-09T13:22:18.216Z","tags":[{"paper_doi":"10.1016/j.cgh.2026.04.015","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.015","tag_type":"brand","value":"Entyvio","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.015","tag_type":"brand","value":"Stelara","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.015","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.015","tag_type":"condition","value":"Crohn's Disease","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.015","tag_type":"condition","value":"Inflammatory Bowel Disease","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.015","tag_type":"condition","value":"Serious Infection","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.015","tag_type":"generic","value":"ustekinumab","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.015","tag_type":"generic","value":"vedolizumab","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.015","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.015","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.015","tag_type":"modality","value":"Aminosalicylate","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.015","tag_type":"modality","value":"Anti-TNF Agent","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.015","tag_type":"modality","value":"IL-12/23 Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.015","tag_type":"modality","value":"Integrin Receptor Antagonist","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.015","tag_type":"modality","value":"JAK Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.015","tag_type":"sample_size","value":"n=219229","value_numeric":219229},{"paper_doi":"10.1016/j.cgh.2026.04.015","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.015","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.015","tag_type":"warning","value":"JAKi group is substantially smaller (n=6,439) compared to anti-TNF (n=93,444), which may affect precision of estimates.","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.015","tag_type":"warning","value":"Median follow-up of 1.0 year is short; long-term infection risk rankings may differ.","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.015","tag_type":"warning","value":"The study is not yet formally published as of today's date (published 2026-04-27) and the DOI suggests in-press status; findings should be interpreted with that in mind.","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.015","tag_type":"warning","value":"Vedolizumab showing higher serious infection risk than anti-TNF (aHR 1.07 vs. aminosalicylates 1.38 vs. 1.29) is counterintuitive given its gut-selective mechanism; residual confounding or channeling bias (more complex patients receiving vedolizumab) may explain this finding.","value_numeric":null}],"summaries":{"what_studied":"Nationwide French cohort of 219,229 IBD patients (>15 years) initiating vedolizumab, ustekinumab, JAK inhibitors (JAKi), anti-TNF, or aminosalicylates between 2014–2024, assessed for serious infection risk using propensity score–weighted analysis over a median follow-up of 1.0 year.","key_result":"15,081 serious infections occurred. Versus aminosalicylates: JAKi carried the highest risk (aHR 1.63, 95%CI 1.45–1.84), followed by vedolizumab (aHR 1.38), anti-TNF (aHR 1.29), and ustekinumab (aHR 1.05, essentially no excess risk). Versus anti-TNF: ustekinumab was safest (aHR 0.81), vedolizumab was similar (aHR 1.07), and JAKi was highest (aHR 1.27). Concomitant corticosteroids nearly doubled risk (aHR 2.06).","limitations":"Median follow-up of only 1.0 year limits long-term risk assessment. Residual confounding is possible despite propensity score weighting, as channel bias (sicker patients routed to specific therapies) may persist. Administrative claims data may miss nuanced clinical details (e.g., disease severity, comorbidities).","practice_takeaway":"When choosing advanced IBD therapy, ustekinumab carries the lowest serious infection risk, while JAKi carries the highest — especially for herpesvirus infections; ensure vaccination and minimize concomitant corticosteroids where possible. Anti-TNF users should be monitored closely for mycobacterial infections, and JAKi users for herpesvirus reactivation."}},{"doi":"10.1016/j.cgh.2026.01.017","pmid":"41616901","title":"Ustekinumab and Janus Kinase Inhibitors Outperform Vedolizumab as Second-Line Therapy in Anti-Tumor Necrosis Factor-Experienced Patients With Ulcerative Colitis","journal_title":"Clinical Gastroenterology and Hepatology","journal_issn":"1542-3565","published_at":"2026-01-29T00:00:00.000Z","url":"https://doi.org/10.1016/j.cgh.2026.01.017","source_score":18,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-27T06:17:02.218Z","updated_at":"2026-08-27T06:17:02.218Z","tags":[{"paper_doi":"10.1016/j.cgh.2026.01.017","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.01.017","tag_type":"brand","value":"Entyvio","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.01.017","tag_type":"brand","value":"Remicade","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.01.017","tag_type":"brand","value":"Stelara","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.01.017","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.01.017","tag_type":"condition","value":"Ulcerative Colitis","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.01.017","tag_type":"generic","value":"infliximab","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.01.017","tag_type":"generic","value":"ustekinumab","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.01.017","tag_type":"generic","value":"vedolizumab","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.01.017","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.01.017","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.01.017","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.01.017","tag_type":"modality","value":"IL-12/23 Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.01.017","tag_type":"modality","value":"Integrin Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.01.017","tag_type":"modality","value":"JAK Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.01.017","tag_type":"sample_size","value":"n=596","value_numeric":596},{"paper_doi":"10.1016/j.cgh.2026.01.017","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.01.017","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.01.017","tag_type":"warning","value":"Full text was not available; key details such as specific JAK inhibitors used, breakdown of adverse event types, and exact steroid-free remission rates (percentages) could not be verified.","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.01.017","tag_type":"warning","value":"Retrospective design with energy balancing weights used to address confounding — residual confounding cannot be excluded.","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.01.017","tag_type":"warning","value":"Study registered on ClinicalTrials.gov (NCT06691061) but published in 2026; trial registration date relative to data collection is unclear.","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.01.017","tag_type":"warning","value":"Ustekinumab is not FDA-approved for ulcerative colitis (only Crohn's disease); its use in UC in this study reflects European real-world practice and may not apply in all regions.","value_numeric":null}],"summaries":{"what_studied":"This retrospective, multicenter European study compared the real-world effectiveness and safety of vedolizumab, ustekinumab, and JAK inhibitors as second-line therapy in 596 adults with ulcerative colitis (UC) who had previously failed anti-TNF-α therapy, over 12 months.","key_result":"Both ustekinumab and JAKi were superior to vedolizumab for steroid-free clinical remission (aHR 1.54 and 1.66, respectively) and biochemical SFCR (aHR 2.26 and 3.37, respectively) at 12 months, with no significant difference between ustekinumab and JAKi. JAKi recipients had ~4× higher adverse event rates vs. vedolizumab and ustekinumab.","limitations":"Retrospective design limits causal inference. Only second-line use was studied, so findings may not generalize to later lines of therapy. Full-text was not available, limiting assessment of specific AE types, JAKi agents used, or granular remission rates.","practice_takeaway":"In anti-TNF-experienced UC patients, ustekinumab or a JAK inhibitor achieves better remission than vedolizumab at 12 months — but JAKi carries a significantly higher adverse event burden, so patient-specific risk factors should guide the choice between them."}},{"doi":"10.1053/j.gastro.2025.09.038","pmid":"41274746","title":"AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn’s Disease","journal_title":"Gastroenterology","journal_issn":"0016-5085","published_at":"2025-11-23T00:00:00.000Z","url":"https://doi.org/10.1053/j.gastro.2025.09.038","source_score":101,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-11-22","doi":"10.1053/j.gastro.2025.09.038","days":"14","issn":"0016-5085","rank":"1","field":"Clinical Medicine","score":"101","category":"Gastroenterology & Hepatology","categories":["Gastroenterology & Hepatology"],"_categories":["Gastroenterology & Hepatology"]},"pubmed":{"doi":"10.1053/j.gastro.2025.09.038","title":"AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn's Disease.","journal":"Gastroenterology","methods":"","results":"$3c","abstract":"$3d","keywords":["Evidence Synthesis","Inflammatory Bowel Disease","Network Meta-Analysis","Positioning"],"pubmed_id":"41274746","conclusions":"","publication_date":"2025-11-23T00:00:00"},"crossref":{"DOI":"10.1053/j.gastro.2025.09.038","URL":"https://doi.org/10.1053/j.gastro.2025.09.038","ISSN":["0016-5085"],"link":[{"URL":"https://api.elsevier.com/content/article/PII:S0016508525060913?httpAccept=text/xml","content-type":"text/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://api.elsevier.com/content/article/PII:S0016508525060913?httpAccept=text/plain","content-type":"text/plain","content-version":"vor","intended-application":"text-mining"}],"page":"1397-1448","type":"journal-article","issue":"7","score":1,"title":["AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn’s Disease"],"author":[{"given":"Frank I.","family":"Scott","sequence":"first","affiliation":[]},{"given":"Ashwin N.","family":"Ananthakrishnan","sequence":"additional","affiliation":[]},{"given":"Benjamin","family":"Click","sequence":"additional","affiliation":[]},{"given":"Manasi","family":"Agrawal","sequence":"additional","affiliation":[]},{"given":"Gaurav","family":"Syal","sequence":"additional","affiliation":[]},{"given":"John P.","family":"Haydek","sequence":"additional","affiliation":[]},{"given":"Yuhong","family":"Yuan","sequence":"additional","affiliation":[]},{"given":"Michael D.","family":"Kappelman","sequence":"additional","affiliation":[]},{"given":"James D.","family":"Lewis","sequence":"additional","affiliation":[]},{"given":"Siddharth","family":"Singh","sequence":"additional","affiliation":[]}],"issued":{"date-parts":[[2025,12]]},"member":"78","prefix":"10.1053","source":"Crossref","volume":"169","created":{"date-time":"2025-11-20T15:58:29Z","timestamp":1763654309000,"date-parts":[[2025,11,20]]},"indexed":{"date-time":"2025-12-02T01:27:12Z","timestamp":1764638832344,"date-parts":[[2025,12,2]]},"license":[{"URL":"https://www.elsevier.com/tdm/userlicense/1.0/","start":{"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000,"date-parts":[[2025,12,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://www.elsevier.com/legal/tdmrep-license","start":{"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000,"date-parts":[[2025,12,1]]},"delay-in-days":0,"content-version":"tdm"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://linkinghub.elsevier.com/retrieve/pii/S0016508525060913"}},"subtitle":[],"assertion":[{"name":"publisher","label":"This article is maintained by","value":"Elsevier"},{"name":"articletitle","label":"Article Title","value":"AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn’s Disease"},{"name":"journaltitle","label":"Journal Title","value":"Gastroenterology"},{"name":"articlelink","label":"CrossRef DOI link to publisher maintained version","value":"https://doi.org/10.1053/j.gastro.2025.09.038"},{"name":"content_type","label":"Content Type","value":"article"},{"name":"copyright","label":"Copyright","value":"© 2025 by the AGA Institute."}],"deposited":{"date-time":"2025-12-02T01:24:45Z","timestamp":1764638685000,"date-parts":[[2025,12,2]]},"issn-type":[{"type":"print","value":"0016-5085"}],"published":{"date-parts":[[2025,12]]},"publisher":"Elsevier BV","reference":[{"DOI":"10.15585/mmwr.mm6542a3","key":"10.1053/j.gastro.2025.09.038_bib1","year":"2016","issue":null,"author":"Dahlhamer","volume":"65","first-page":"1166","unstructured":null,"article-title":"Prevalence of inflammatory bowel disease among adults aged ≥18 years — United States, 2015","journal-title":"MMWR Morb Mortal Wkly Rep","doi-asserted-by":"crossref"},{"DOI":"10.1016/S2468-1253(19)30333-4","key":"10.1053/j.gastro.2025.09.038_bib2","year":"2020","issue":null,"author":null,"volume":"5","first-page":"17","unstructured":null,"article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","journal-title":"Lancet Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2023.07.003","key":"10.1053/j.gastro.2025.09.038_bib3","year":"2023","issue":null,"author":"Lewis","volume":"165","first-page":"1197","unstructured":null,"article-title":"Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1136/gutjnl-2013-305607","key":"10.1053/j.gastro.2025.09.038_bib4","year":"2014","issue":null,"author":"Rungoe","volume":"63","first-page":"1607","unstructured":null,"article-title":"Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979–2011","journal-title":"Gut","doi-asserted-by":"crossref"},{"DOI":"10.1007/s10620-021-07200-1","key":"10.1053/j.gastro.2025.09.038_bib5","year":"2022","issue":null,"author":"Tsai","volume":"67","first-page":"2451","unstructured":null,"article-title":"Systematic review and meta-analysis: risk of hospitalization in patients with ulcerative colitis and Crohn's Disease in population-based cohort studies","journal-title":"Dig Dis Sci","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2021.04.023","key":"10.1053/j.gastro.2025.09.038_bib6","year":"2021","issue":null,"author":"Singh","volume":"160","first-page":"2512","unstructured":null,"article-title":"AGA technical review on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1136/gutjnl-2016-312648","key":"10.1053/j.gastro.2025.09.038_bib7","year":"2018","issue":null,"author":"Siegel","volume":"67","first-page":"244","unstructured":null,"article-title":"Development of an index to define overall disease severity in IBD","journal-title":"Gut","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2014.07.022","key":"10.1053/j.gastro.2025.09.038_bib8","year":"2014","issue":null,"author":"Sandborn","volume":"147","first-page":"702","unstructured":null,"article-title":"Crohn’s disease evaluation and treatment: clinical decision tool","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2013.02.001","key":"10.1053/j.gastro.2025.09.038_bib9","year":"2013","issue":null,"author":"Sultan","volume":"11","first-page":"329","unstructured":null,"article-title":"The AGA institute process for developing clinical practice guidelines part one: grading the evidence","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2025.08.032","key":"10.1053/j.gastro.2025.09.038_bib10","year":"2025","issue":null,"author":"Singh","volume":"169","first-page":"1516","unstructured":null,"article-title":"Comparative efficacy of advanced therapies for management of moderate-to-severe Crohn’s disease: 2025 AGA evidence synthesis","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.7326/M22-0514","key":"10.1053/j.gastro.2025.09.038_bib11","year":"2022","issue":null,"author":"El Mikati","volume":"175","first-page":"1154","unstructured":null,"article-title":"A framework for the development of living practice guidelines in health care","journal-title":"Ann Intern Med","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2023.09.029","key":"10.1053/j.gastro.2025.09.038_bib12","year":"2023","issue":null,"author":"Ananthakrishnan","volume":"165","first-page":"1367","unstructured":null,"article-title":"AGA clinical practice guideline on the role of biomarkers for the management of Crohn's disease","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.dld.2016.09.009","key":"10.1053/j.gastro.2025.09.038_bib13","year":"2017","issue":null,"author":"Casellas","volume":"49","first-page":"152","unstructured":null,"article-title":"Patient preferences for inflammatory bowel disease treatment objectives","journal-title":"Dig Liver Dis","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0016-5085(76)80163-1","key":"10.1053/j.gastro.2025.09.038_bib14","year":"1976","issue":null,"author":"Best","volume":"70","first-page":"439","unstructured":null,"article-title":"Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2024.10.001","key":"10.1053/j.gastro.2025.09.038_bib15","year":"2024","issue":null,"author":"Singh","volume":"167","first-page":"1307","unstructured":null,"article-title":"AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1016/0197-2456(86)90046-2","key":"10.1053/j.gastro.2025.09.038_bib16","year":"1986","issue":null,"author":"DerSimonian","volume":"7","first-page":"177","unstructured":null,"article-title":"Meta-analysis in clinical trials","journal-title":"Control Clin Trials","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2024.10.009","key":"10.1053/j.gastro.2025.09.038_bib17","year":"2025","issue":null,"author":"Solitano","volume":"168","first-page":"344","unstructured":null,"article-title":"Placebo rates in Crohn's disease randomized clinical trials: an individual patient data meta-analysis","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1136/bmj.327.7414.557","key":"10.1053/j.gastro.2025.09.038_bib18","year":"2003","issue":null,"author":"Higgins","volume":"327","first-page":"557","unstructured":null,"article-title":"Measuring inconsistency in meta-analyses","journal-title":"BMJ","doi-asserted-by":"crossref"},{"DOI":"10.1136/bmj.d4002","key":"10.1053/j.gastro.2025.09.038_bib19","year":"2011","issue":null,"author":"Sterne","volume":"343","first-page":null,"unstructured":null,"article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","journal-title":"BMJ","doi-asserted-by":"crossref"},{"DOI":"10.1136/bmj-2022-074495","key":"10.1053/j.gastro.2025.09.038_bib20","year":"2023","issue":null,"author":"Izcovich","volume":"381","first-page":null,"unstructured":null,"article-title":"A guide and pragmatic considerations for applying GRADE to network meta-analysis","journal-title":"BMJ","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jclinepi.2017.10.005","key":"10.1053/j.gastro.2025.09.038_bib21","year":"2018","issue":null,"author":"Brignardello-Petersen","volume":"93","first-page":"36","unstructured":null,"article-title":"Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis","journal-title":"J Clin Epidemiol","doi-asserted-by":"crossref"},{"DOI":"10.1093/ibd/izaf085","key":"10.1053/j.gastro.2025.09.038_bib22","year":"2025","issue":null,"author":"Gordon","volume":"31","first-page":"2798","unstructured":null,"article-title":"Developing IBD outcome effect size thresholds to inform research, guidelines, and clinical decisions","journal-title":"Inflamm Bowel Dis","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1053/j.gastro.2025.09.038_bib23","year":"2016","issue":null,"author":"Alonso-Coello","volume":"353","first-page":null,"unstructured":null,"article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction","journal-title":"BMJ","doi-asserted-by":null},{"DOI":"10.1016/S2468-1253(20)30300-9","key":"10.1053/j.gastro.2025.09.038_bib24","year":"2020","issue":null,"author":"Fairbrass","volume":"5","first-page":"1053","unstructured":null,"article-title":"Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis","journal-title":"Lancet Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s11938-021-00364-9","key":"10.1053/j.gastro.2025.09.038_bib25","year":"2021","issue":null,"author":"Hashash","volume":"19","first-page":"583","unstructured":null,"article-title":"Health maintenance for adult patients with inflammatory bowel disease","journal-title":"Cur Treat Options Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2009.11.024","key":"10.1053/j.gastro.2025.09.038_bib26","year":"2010","issue":null,"author":"Long","volume":"8","first-page":"268","unstructured":null,"article-title":"Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2012.05.004","key":"10.1053/j.gastro.2025.09.038_bib27","year":"2012","issue":null,"author":"Long","volume":"143","first-page":"390","unstructured":null,"article-title":"Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1001/jama.2017.16071","key":"10.1053/j.gastro.2025.09.038_bib28","year":"2017","issue":null,"author":"Lemaitre","volume":"318","first-page":"1679","unstructured":null,"article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease","journal-title":"JAMA","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa2109927","key":"10.1053/j.gastro.2025.09.038_bib29","year":"2022","issue":null,"author":"Ytterberg","volume":"386","first-page":"316","unstructured":null,"article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1038/ajg.2015.233","key":"10.1053/j.gastro.2025.09.038_bib30","year":"2015","issue":null,"author":"Peyrin-Biroulet","volume":"110","first-page":"1324","unstructured":null,"article-title":"Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target","journal-title":"Am J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2020.12.031","key":"10.1053/j.gastro.2025.09.038_bib31","year":"2021","issue":null,"author":"Turner","volume":"160","first-page":"1570","unstructured":null,"article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJM199710093371502","key":"10.1053/j.gastro.2025.09.038_bib32","year":"1997","issue":null,"author":"Targan","volume":"337","first-page":"1029","unstructured":null,"article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2006.02.014","key":"10.1053/j.gastro.2025.09.038_bib33","year":"2006","issue":null,"author":"Lemann","volume":"130","first-page":"1054","unstructured":null,"article-title":"Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(02)08512-4","key":"10.1053/j.gastro.2025.09.038_bib34","year":"2002","issue":null,"author":"Hanauer","volume":"359","first-page":"1541","unstructured":null,"article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2024.05.006","key":"10.1053/j.gastro.2025.09.038_bib35","year":"2024","issue":null,"author":"Hanauer","volume":"167","first-page":"919","unstructured":null,"article-title":"Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for inflammatory bowel disease: two randomized phase 3 trials (LIBERTY)","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0016-5085(99)70332-X","key":"10.1053/j.gastro.2025.09.038_bib36","year":"1999","issue":null,"author":"Rutgeerts","volume":"117","first-page":"761","unstructured":null,"article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2005.11.030","key":"10.1053/j.gastro.2025.09.038_bib37","year":"2006","issue":null,"author":"Hanauer","volume":"130","first-page":"323","unstructured":null,"article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1136/gut.2006.106781","key":"10.1053/j.gastro.2025.09.038_bib38","year":"2007","issue":null,"author":"Sandborn","volume":"56","first-page":"1232","unstructured":null,"article-title":"Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial","journal-title":"Gut","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.crohns.2011.07.013","key":"10.1053/j.gastro.2025.09.038_bib39","year":"2012","issue":null,"author":"Watanabe","volume":"6","first-page":"160","unstructured":null,"article-title":"Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease","journal-title":"J Crohns Colitis","doi-asserted-by":"crossref"},{"DOI":"10.1177/1756284820938960","key":"10.1053/j.gastro.2025.09.038_bib40","year":"2020","issue":null,"author":"Chen","volume":"13","first-page":null,"unstructured":null,"article-title":"Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial","journal-title":"Ther Adv Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.7326/0003-4819-146-12-200706190-00159","key":"10.1053/j.gastro.2025.09.038_bib41","year":"2007","issue":null,"author":"Sandborn","volume":"146","first-page":"829","unstructured":null,"article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial","journal-title":"Ann Intern Med","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2006.11.041","key":"10.1053/j.gastro.2025.09.038_bib42","year":"2007","issue":null,"author":"Colombel","volume":"132","first-page":"52","unstructured":null,"article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2012.01.035","key":"10.1053/j.gastro.2025.09.038_bib43","year":"2012","issue":null,"author":"Rutgeerts","volume":"142","first-page":"1102","unstructured":null,"article-title":"Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND Trial","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa067594","key":"10.1053/j.gastro.2025.09.038_bib44","year":"2007","issue":null,"author":"Sandborn","volume":"357","first-page":"228","unstructured":null,"article-title":"Certolizumab pegol for the treatment of Crohn's disease","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa062897","key":"10.1053/j.gastro.2025.09.038_bib45","year":"2007","issue":null,"author":"Schreiber","volume":"357","first-page":"239","unstructured":null,"article-title":"Maintenance therapy with certolizumab pegol for Crohn's disease","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2010.04.021","key":"10.1053/j.gastro.2025.09.038_bib46","year":"2010","issue":null,"author":"Sandborn","volume":"8","first-page":"688","unstructured":null,"article-title":"Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa1215739","key":"10.1053/j.gastro.2025.09.038_bib47","year":"2013","issue":null,"author":"Sandborn","volume":"369","first-page":"711","unstructured":null,"article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2014.05.008","key":"10.1053/j.gastro.2025.09.038_bib48","year":"2014","issue":null,"author":"Sands","volume":"147","first-page":"618","unstructured":null,"article-title":"Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00535-019-01647-w","key":"10.1053/j.gastro.2025.09.038_bib49","year":"2020","issue":null,"author":"Watanabe","volume":"55","first-page":"291","unstructured":null,"article-title":"Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses","journal-title":"J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1093/ecco-jcc/jjab133","key":"10.1053/j.gastro.2025.09.038_bib50","year":"2022","issue":null,"author":"Vermeire","volume":"16","first-page":"27","unstructured":null,"article-title":"Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active Crohn's disease: results from the VISIBLE 2 randomised trial","journal-title":"J Crohns Colitis","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa1203572","key":"10.1053/j.gastro.2025.09.038_bib51","year":"2012","issue":null,"author":"Sandborn","volume":"367","first-page":"1519","unstructured":null,"article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn's disease","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa1602773","key":"10.1053/j.gastro.2025.09.038_bib52","year":"2016","issue":null,"author":"Feagan","volume":"375","first-page":"1946","unstructured":null,"article-title":"Ustekinumab as induction and maintenance therapy for Crohn's disease","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2008.07.014","key":"10.1053/j.gastro.2025.09.038_bib53","year":"2008","issue":null,"author":"Sandborn","volume":"135","first-page":"1130","unstructured":null,"article-title":"A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0016-5085(24)05019-4","key":"10.1053/j.gastro.2025.09.038_bib54","year":"2024","issue":null,"author":"Panaccione","volume":"166","first-page":"1057b2","unstructured":null,"article-title":"Efficacy and safety of guselkumab therapy in patients with moderately to severely active Crohn's disease: results of the GALAXI 2 & 3 phase 3 studies","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2022.01.047","key":"10.1053/j.gastro.2025.09.038_bib55","year":"2022","issue":null,"author":"Sandborn","volume":"162","first-page":"1650","unstructured":null,"article-title":"Guselkumab for the treatment of Crohn's disease: induction results from the phase 2 GALAXI-1 study","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(24)01762-8","key":"10.1053/j.gastro.2025.09.038_bib56","year":"2024","issue":null,"author":"Ferrante","volume":"404","first-page":"2423","unstructured":null,"article-title":"Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2021.10.050","key":"10.1053/j.gastro.2025.09.038_bib57","year":"2022","issue":null,"author":"Sands","volume":"162","first-page":"495","unstructured":null,"article-title":"Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with Crohn's disease","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2025.02.033","key":"10.1053/j.gastro.2025.09.038_bib58","year":"2025","issue":null,"author":"Hart","volume":"169","first-page":"308","unstructured":null,"article-title":"Efficacy and safety of guselkumab subcutaneous induction and maintenance in participants with moderately to severely active Crohn’s disease: results from the phase 3 GRAVITI study","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(22)00467-6","key":"10.1053/j.gastro.2025.09.038_bib59","year":"2022","issue":null,"author":"D'Haens","volume":"399","first-page":"2015","unstructured":null,"article-title":"Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(17)30570-6","key":"10.1053/j.gastro.2025.09.038_bib60","year":"2017","issue":null,"author":"Feagan","volume":"389","first-page":"1699","unstructured":null,"article-title":"Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(22)00466-4","key":"10.1053/j.gastro.2025.09.038_bib61","year":"2022","issue":null,"author":"Ferrante","volume":"399","first-page":"2031","unstructured":null,"article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa2212728","key":"10.1053/j.gastro.2025.09.038_bib62","year":"2023","issue":null,"author":"Loftus","volume":"388","first-page":"1966","unstructured":null,"article-title":"Upadacitinib induction and maintenance therapy for Crohn’s disease","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2020.01.047","key":"10.1053/j.gastro.2025.09.038_bib63","year":"2020","issue":null,"author":"Sandborn","volume":"158","first-page":"2123","unstructured":null,"article-title":"Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn's disease","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1093/ecco-jcc/jjad100","key":"10.1053/j.gastro.2025.09.038_bib64","year":"2023","issue":null,"author":"Solitano","volume":"17","first-page":"1800","unstructured":null,"article-title":"Efficacy and safety of advanced oral small molecules for inflammatory bowel disease: systematic review and meta-analysis","journal-title":"J Crohns Colitis","doi-asserted-by":"crossref"},{"DOI":"10.1038/ajg.2016.433","key":"10.1053/j.gastro.2025.09.038_bib66","year":"2016","issue":null,"author":"Osterman","volume":"111","first-page":"1806","unstructured":null,"article-title":"Crohn's disease activity and concomitant immunosuppressants affect the risk of serious and opportunistic infections in patients treated with adalimumab","journal-title":"Am J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1038/ajg.2012.218","key":"10.1053/j.gastro.2025.09.038_bib67","year":"2012","issue":null,"author":"Lichtenstein","volume":"107","first-page":"1409","unstructured":null,"article-title":"Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry","journal-title":"Am J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2024.01.003","key":"10.1053/j.gastro.2025.09.038_bib68","year":"2024","issue":null,"author":"Ahuja","volume":"22","first-page":"1286","unstructured":null,"article-title":"Impact of treatment response on risk of serious infections in patients with Crohn's disease: secondary analysis of the PYRAMID registry","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1093/ibd/izy321","key":"10.1053/j.gastro.2025.09.038_bib69","year":"2019","issue":null,"author":"Scott","volume":"25","first-page":"925","unstructured":null,"article-title":"Improved quality of life with anti-TNF therapy compared with continued corticosteroid utilization in Crohn's disease","journal-title":"Inflamm Bowel Dis","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2019.05.010","key":"10.1053/j.gastro.2025.09.038_bib70","year":"2020","issue":null,"author":"Bewtra","volume":"18","first-page":"406","unstructured":null,"article-title":"Variation among patients with Crohn's disease in benefit vs risk preferences and remission time equivalents","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.14309/ctg.0000000000000629","key":"10.1053/j.gastro.2025.09.038_bib71","year":"2023","issue":null,"author":"Hanzel","volume":"14","first-page":null,"unstructured":null,"article-title":"A comparison of treatment effect sizes in matched phase 2 and phase 3 trials of advanced therapeutics in inflammatory bowel disease: systematic review and meta-analysis","journal-title":"Clin Transl Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(17)30068-5","key":"10.1053/j.gastro.2025.09.038_bib72","year":"2017","issue":null,"author":"Jorgensen","volume":"389","first-page":"2304","unstructured":null,"article-title":"Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1053/j.gastro.2025.09.038_bib73","year":"2025","issue":"Suppl 1","author":"Elosua Gonzalez","volume":"19","first-page":null,"unstructured":null,"article-title":"P0990 Real-world effectiveness of upadacitinib induction therapy in Crohn’s disease, with a focus on patients with concomitant IMIDs","journal-title":"J Crohns Colitis","doi-asserted-by":null},{"DOI":"10.14309/01.ajg.0001034600.37922.a6","key":"10.1053/j.gastro.2025.09.038_bib74","year":"2024","issue":"Suppl","author":"Axenfeld","volume":"119","first-page":"S936","unstructured":null,"article-title":"S1308 Treatment outcomes of prolonged induction or re-escalation dosing of upadacitinib in patients with inflammatory bowel disease","journal-title":"Am J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2024.12.023","key":"10.1053/j.gastro.2025.09.038_bib75","year":"2025","issue":null,"author":"Panaccione","volume":"23","first-page":"2012","unstructured":null,"article-title":"Extended risankizumab treatment in patients with Crohn's disease who did not achieve clinical response to induction treatment","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1053/j.gastro.2025.09.038_bib76","year":"2025","issue":"Suppl","author":"Afzali","volume":"13","first-page":"S576","unstructured":null,"article-title":"Abstract MP582. Guselkumab maintenance dose regimens in patients with high disease activity and severity: subgroup analysis of participants with moderately to severely active Crohn's disease in the GALAXI phase 3 studies","journal-title":"United European Gastroenterol J","doi-asserted-by":null},{"DOI":null,"key":"10.1053/j.gastro.2025.09.038_bib77","year":"2022","issue":null,"author":"Alayo","volume":"4","first-page":null,"unstructured":null,"article-title":"Systematic review with meta-analysis: safety and effectiveness of combining biologics and small molecules in inflammatory bowel disease","journal-title":"Crohns Colitis 360","doi-asserted-by":null},{"DOI":"10.1016/j.cgh.2024.05.051","key":"10.1053/j.gastro.2025.09.038_bib78","year":"2025","issue":null,"author":"Battat","volume":"23","first-page":"469","unstructured":null,"article-title":"IBD matchmaking: rational combination therapy","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2011.04.031","key":"10.1053/j.gastro.2025.09.038_bib79","year":"2011","issue":null,"author":"Sandborn","volume":"9","first-page":"670","unstructured":null,"article-title":"Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(22)00688-2","key":"10.1053/j.gastro.2025.09.038_bib80","year":"2022","issue":null,"author":"Sands","volume":"399","first-page":"2200","unstructured":null,"article-title":"Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa2314585","key":"10.1053/j.gastro.2025.09.038_bib81","year":"2024","issue":null,"author":"Peyrin-Biroulet","volume":"391","first-page":"213","unstructured":null,"article-title":"Risankizumab versus ustekinumab for moderate-to-severe Crohn's disease","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2025.07.009","key":"10.1053/j.gastro.2025.09.038_bib82","year":"2025","issue":null,"author":"Lee","volume":null,"first-page":null,"unstructured":null,"article-title":"Efficacy of advanced therapies in achieving remission by disease location in Crohn's disease: a systematic review and meta-analysis","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1136/gutjnl-2024-334395","key":"10.1053/j.gastro.2025.09.038_bib83","year":"2025","issue":"Suppl 2","author":"Moran","volume":"74","first-page":"s1","unstructured":null,"article-title":"British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025","journal-title":"Gut","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2023.12.023","key":"10.1053/j.gastro.2025.09.038_bib84","year":"2024","issue":null,"author":"Vuyyuru","volume":"22","first-page":"1190","unstructured":null,"article-title":"Comparative efficacy of advanced therapies for achieving endoscopic outcomes in crohn's disease: a systematic review and network meta-analysis","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2019.11.267","key":"10.1053/j.gastro.2025.09.038_bib85","year":"2020","issue":null,"author":"Dolinger","volume":"158","first-page":null,"unstructured":null,"article-title":"P082 Anti-TNF efficacy after primary vedolizumab failure in pediatric inflammatory bowel disease","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1093/ecco-jcc/jjab058","key":"10.1053/j.gastro.2025.09.038_bib86","year":"2021","issue":null,"author":"Bressler","volume":"15","first-page":"1694","unstructured":null,"article-title":"Vedolizumab and anti-tumour necrosis factor α real-world outcomes in biologic-naïve inflammatory bowel disease patients: results from the EVOLVE study","journal-title":"J Crohns Colitis","doi-asserted-by":"crossref"},{"DOI":"10.14309/ajg.0000000000002553","key":"10.1053/j.gastro.2025.09.038_bib87","year":"2024","issue":null,"author":"Chugh","volume":"119","first-page":"468","unstructured":null,"article-title":"Maternal and neonatal outcomes in vedolizumab- and ustekinumab-exposed pregnancies: results from the PIANO registry","journal-title":"Am J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2024.06.050","key":"10.1053/j.gastro.2025.09.038_bib88","year":"2025","issue":null,"author":"Fudman","volume":"23","first-page":"454","unstructured":null,"article-title":"Modern advanced therapies for inflammatory bowel diseases: practical considerations and positioning","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S2468-1253(25)00017-2","key":"10.1053/j.gastro.2025.09.038_bib89","year":"2025","issue":null,"author":"Panaccione","volume":"10","first-page":"507","unstructured":null,"article-title":"Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study","journal-title":"Lancet Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2021.12.030","key":"10.1053/j.gastro.2025.09.038_bib90","year":"2022","issue":null,"author":"D’Haens","volume":"20","first-page":"2337","unstructured":null,"article-title":"Upadacitinib was efficacious and well-tolerated over 30 months in patients with Crohn’s disease in the CELEST extension study","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjd.20818","key":"10.1053/j.gastro.2025.09.038_bib91","year":"2022","issue":null,"author":"Gordon","volume":"186","first-page":"466","unstructured":null,"article-title":"Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1093/ecco-jcc/jjab093","key":"10.1053/j.gastro.2025.09.038_bib92","year":"2021","issue":null,"author":"Ferrante","volume":"15","first-page":"2001","unstructured":null,"article-title":"Long-term safety and efficacy of risankizumab treatment in patients with Crohn's disease: results from the phase 2 open-label extension study","journal-title":"J Crohns Colitis","doi-asserted-by":"crossref"},{"DOI":"10.1136/gut.37.5.674","key":"10.1053/j.gastro.2025.09.038_bib93","year":"1995","issue":null,"author":"Candy","volume":"37","first-page":"674","unstructured":null,"article-title":"A controlled double blind study of azathioprine in the management of Crohn's disease","journal-title":"Gut","doi-asserted-by":"crossref"},{"DOI":"10.1016/0016-5085(93)90709-L","key":"10.1053/j.gastro.2025.09.038_bib94","year":"1993","issue":null,"author":"Ewe","volume":"105","first-page":"367","unstructured":null,"article-title":"Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1053/j.gastro.2025.09.038_bib95","year":"1997","issue":null,"author":"Oren","volume":"92","first-page":"2203","unstructured":null,"article-title":"Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial","journal-title":"Am J Gastroenterol","doi-asserted-by":null},{"DOI":"10.1111/j.1572-0241.2008.02024.x","key":"10.1053/j.gastro.2025.09.038_bib96","year":"2008","issue":null,"author":"Reinisch","volume":"103","first-page":"2284","unstructured":null,"article-title":"A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease","journal-title":"Am J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1016/0016-5085(79)90385-8","key":"10.1053/j.gastro.2025.09.038_bib97","year":"1979","issue":null,"author":"Summers","volume":"77","first-page":"847","unstructured":null,"article-title":"National Cooperative Crohn's Disease Study: results of drug treatment","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1053/gast.2000.18144","key":"10.1053/j.gastro.2025.09.038_bib98","year":"2000","issue":null,"author":"Markowitz","volume":"119","first-page":"895","unstructured":null,"article-title":"A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(78)92524-2","key":"10.1053/j.gastro.2025.09.038_bib99","year":"1978","issue":null,"author":"O'Donoghue","volume":"2","first-page":"955","unstructured":null,"article-title":"Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2013.06.009","key":"10.1053/j.gastro.2025.09.038_bib100","year":"2013","issue":null,"author":"Panes","volume":"145","first-page":"766","unstructured":null,"article-title":"Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJM199502023320503","key":"10.1053/j.gastro.2025.09.038_bib101","year":"1995","issue":null,"author":"Feagan","volume":"332","first-page":"292","unstructured":null,"article-title":"Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1053/j.gastro.2025.09.038_bib102","year":"1999","issue":null,"author":"Arora","volume":"46","first-page":"1724","unstructured":null,"article-title":"Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial","journal-title":"Hepatogastroenterology","doi-asserted-by":null},{"DOI":null,"key":"10.1053/j.gastro.2025.09.038_bib103","year":"2000","issue":null,"author":"Feagan","volume":null,"first-page":"342L1627","unstructured":null,"article-title":"A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators","journal-title":"N Engl J Med","doi-asserted-by":null},{"DOI":"10.1001/jamadermatol.2015.3029","key":"10.1053/j.gastro.2025.09.038_bib104","year":"2016","issue":null,"author":"Scott","volume":"152","first-page":"164","unstructured":null,"article-title":"Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer","journal-title":"JAMA Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00384-006-0202-x","key":"10.1053/j.gastro.2025.09.038_bib105","year":"2007","issue":null,"author":"Crispino","volume":"22","first-page":"553","unstructured":null,"article-title":"Hematological malignancies in chronic inflammatory bowel diseases: report of five cases and review of the literature","journal-title":"Int J Colorectal Dis","doi-asserted-by":"crossref"},{"DOI":"10.1001/jama.1971.03180310117023","key":"10.1053/j.gastro.2025.09.038_bib106","year":"1971","issue":null,"author":"Filip","volume":"216","first-page":"881","unstructured":null,"article-title":"Pulmonary and hepatic complications of methotrexate therapy of psoriasis","journal-title":"JAMA","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2014.05.015","key":"10.1053/j.gastro.2025.09.038_bib107","year":"2015","issue":null,"author":"Kotlyar","volume":"13","first-page":"847","unstructured":null,"article-title":"Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1038/ajg.2013.402","key":"10.1053/j.gastro.2025.09.038_bib108","year":"2014","issue":null,"author":"Chatu","volume":"109","first-page":"23","unstructured":null,"article-title":"The role of thiopurines in reducing the need for surgical resection in Crohn's disease: a systematic review and meta-analysis","journal-title":"Am J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2017.07.032","key":"10.1053/j.gastro.2025.09.038_bib109","year":"2017","issue":null,"author":"Feuerstein","volume":"153","first-page":"827","unstructured":null,"article-title":"American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2023.03.224","key":"10.1053/j.gastro.2025.09.038_bib110","year":"2023","issue":null,"author":"Kappelman","volume":"165","first-page":"149","unstructured":null,"article-title":"Comparative effectiveness of anti-TNF in combination with low-dose methotrexate vs anti-TNF monotherapy in pediatric Crohn's disease: a pragmatic randomized trial","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa0904492","key":"10.1053/j.gastro.2025.09.038_bib111","year":"2010","issue":null,"author":"Colombel","volume":"362","first-page":"1383","unstructured":null,"article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2013.11.024","key":"10.1053/j.gastro.2025.09.038_bib112","year":"2014","issue":null,"author":"Feagan","volume":"146","first-page":"681","unstructured":null,"article-title":"Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1093/ecco-jcc/jjw152","key":"10.1053/j.gastro.2025.09.038_bib113","year":"2016","issue":null,"author":"Matsumoto","volume":"10","first-page":"1259","unstructured":null,"article-title":"Adalimumab monotherapy and a combination with azathioprine for Crohn's disease: a prospective, randomized trial","journal-title":"J Crohns Colitis","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2013.12.025","key":"10.1053/j.gastro.2025.09.038_bib114","year":"2014","issue":null,"author":"Osterman","volume":"146","first-page":"941","unstructured":null,"article-title":"Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2019.02.044","key":"10.1053/j.gastro.2025.09.038_bib115","year":"2020","issue":null,"author":"Singh","volume":"18","first-page":"69","unstructured":null,"article-title":"Comparative risk of serious infections with biologic and/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta-analysis","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2015.06.034","key":"10.1053/j.gastro.2025.09.038_bib116","year":"2015","issue":null,"author":"Jones","volume":"13","first-page":"2233","unstructured":null,"article-title":"Effects of concomitant immunomodulator therapy on efficacy and safety of anti-tumor necrosis factor therapy for Crohn's disease: a meta-analysis of placebo-controlled trials","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1136/gut.2006.099978","key":"10.1053/j.gastro.2025.09.038_bib117","year":"2007","issue":null,"author":"Vermeire","volume":"56","first-page":"1226","unstructured":null,"article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease","journal-title":"Gut","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2014.12.026","key":"10.1053/j.gastro.2025.09.038_bib118","year":"2015","issue":null,"author":"Yarur","volume":"13","first-page":"1118","unstructured":null,"article-title":"Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2022.10.016","key":"10.1053/j.gastro.2025.09.038_bib119","year":"2023","issue":null,"author":"Yarur","volume":"21","first-page":"2908","unstructured":null,"article-title":"Combination therapy with immunomodulators improves the pharmacokinetics of infliximab but not vedolizumab or ustekinumab","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2019.09.041","key":"10.1053/j.gastro.2025.09.038_bib120","year":"2020","issue":null,"author":"Sazonovs","volume":"158","first-page":"189","unstructured":null,"article-title":"HLA-DQA1∗05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn's disease","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2023.03.044","key":"10.1053/j.gastro.2025.09.038_bib121","year":"2023","issue":null,"author":"Solitano","volume":"21","first-page":"3019","unstructured":null,"article-title":"HLA-DQA1 ∗05 genotype and immunogenicity to tumor necrosis factor-alpha antagonists: a systematic review and meta-analysis","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1136/gutjnl-2019-319758","key":"10.1053/j.gastro.2025.09.038_bib122","year":"2020","issue":null,"author":"Roblin","volume":"69","first-page":"1206","unstructured":null,"article-title":"Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial","journal-title":"Gut","doi-asserted-by":"crossref"},{"DOI":"10.1111/imj.16504","key":"10.1053/j.gastro.2025.09.038_bib123","year":"2024","issue":null,"author":"Yu","volume":"54","first-page":"1856","unstructured":null,"article-title":"6-Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapy","journal-title":"Intern Med J","doi-asserted-by":"crossref"},{"DOI":"10.14309/ajg.0000000000003573","key":"10.1053/j.gastro.2025.09.038_bib124","year":"2025","issue":null,"author":"Solitano","volume":null,"first-page":null,"unstructured":null,"article-title":"Effectiveness and safety of advanced combination treatment in patients with refractory inflammatory bowel disease or concomitant immune-mediated disease or extraintestinal manifestations: a multicenter Canadian study","journal-title":"Am J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2021.03.034","key":"10.1053/j.gastro.2025.09.038_bib125","year":"2022","issue":null,"author":"Ahmed","volume":"20","first-page":"e361","unstructured":null,"article-title":"Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: a systematic review and meta-analysis","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2020.07.012","key":"10.1053/j.gastro.2025.09.038_bib126","year":"2021","issue":null,"author":"Hu","volume":"19","first-page":"1366","unstructured":null,"article-title":"Combination therapy does not improve rate of clinical or endoscopic remission in patients with inflammatory bowel diseases treated with vedolizumab or ustekinumab","journal-title":"Clin Gastroenterolo Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2020.06.071","key":"10.1053/j.gastro.2025.09.038_bib127","year":"2021","issue":null,"author":"Yzet","volume":"19","first-page":"668","unstructured":null,"article-title":"No benefit of concomitant immunomodulator therapy on efficacy of biologics that are not tumor necrosis factor antagonists in patients with inflammatory bowel diseases: a meta-analysis","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.3390/jcm9103142","key":"10.1053/j.gastro.2025.09.038_bib128","year":"2020","issue":null,"author":"Vaughn","volume":"9","first-page":"3142","unstructured":null,"article-title":"Vedolizumab serum trough concentrations and response to dose escalation in inflammatory bowel disease","journal-title":"J Clin Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2021.01.002","key":"10.1053/j.gastro.2025.09.038_bib129","year":"2021","issue":null,"author":"Shukla","volume":"19","first-page":"1108","unstructured":null,"article-title":"Therapeutic drug monitoring of non-anti-tumor necrosis factor biologics","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1136/gutjnl-2022-327002","key":"10.1053/j.gastro.2025.09.038_bib130","year":"2022","issue":null,"author":"Kirchgesner","volume":"71","first-page":"1781","unstructured":null,"article-title":"Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn's disease","journal-title":"Gut","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00535-019-01582-w","key":"10.1053/j.gastro.2025.09.038_bib131","year":"2019","issue":null,"author":"Hisamatsu","volume":"54","first-page":"860","unstructured":null,"article-title":"Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2)","journal-title":"J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1111/apt.14106","key":"10.1053/j.gastro.2025.09.038_bib132","year":"2017","issue":null,"author":"Roblin","volume":"46","first-page":"142","unstructured":null,"article-title":"Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial","journal-title":"Aliment Pharmacol Ther","doi-asserted-by":"crossref"},{"DOI":"10.1097/MPG.0000000000000684","key":"10.1053/j.gastro.2025.09.038_bib133","year":"2015","issue":null,"author":"Kierkus","volume":"60","first-page":"580","unstructured":null,"article-title":"Monotherapy with infliximab versus combination therapy in the maintenance of clinical remission in children with moderate to severe Crohn disease","journal-title":"J Pediatr Gastroenterol Nutr","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2008.03.004","key":"10.1053/j.gastro.2025.09.038_bib134","year":"2008","issue":null,"author":"Van Assche","volume":"134","first-page":"1861","unstructured":null,"article-title":"Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1136/gutjnl-2024-333385","key":"10.1053/j.gastro.2025.09.038_bib135","year":"2025","issue":null,"author":"Gisbert","volume":"74","first-page":"387","unstructured":null,"article-title":"Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU","journal-title":"Gut","doi-asserted-by":"crossref"},{"DOI":"10.1016/S2468-1253(22)00385-5","key":"10.1053/j.gastro.2025.09.038_bib136","year":"2023","issue":null,"author":"Louis","volume":"8","first-page":"215","unstructured":null,"article-title":"Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial","journal-title":"Lancet Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1056/EVIDoa2200061","key":"10.1053/j.gastro.2025.09.038_bib137","year":"2022","issue":null,"author":"Buhl","volume":"1","first-page":null,"unstructured":null,"article-title":"Discontinuation of infliximab therapy in patients with Crohn's disease","journal-title":"NEJM Evid","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2018.04.012","key":"10.1053/j.gastro.2025.09.038_bib138","year":"2018","issue":null,"author":"Kirchgesner","volume":"155","first-page":"337","unstructured":null,"article-title":"Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1136/bmj.h2809","key":"10.1053/j.gastro.2025.09.038_bib139","year":"2015","issue":null,"author":"Nyboe Andersen","volume":"350","first-page":null,"unstructured":null,"article-title":"Association between tumour necrosis factor-alpha inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study","journal-title":"BMJ","doi-asserted-by":"crossref"},{"DOI":"10.14309/ajg.0000000000001058","key":"10.1053/j.gastro.2025.09.038_bib140","year":"2021","issue":null,"author":"Khan","volume":"116","first-page":"741","unstructured":null,"article-title":"Incidence of acute myeloid leukemia and myelodysplastic syndrome in patients with inflammatory bowel disease and the impact of thiopurines on their risk","journal-title":"Am J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2022.01.019","key":"10.1053/j.gastro.2025.09.038_bib141","year":"2022","issue":null,"author":"Mahmoud","volume":"20","first-page":"2577","unstructured":null,"article-title":"Immunomodulator withdrawal from anti-TNF therapy is not associated with loss of response in inflammatory bowel disease","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(08)60304-9","key":"10.1053/j.gastro.2025.09.038_bib142","year":"2008","issue":null,"author":"D'Haens","volume":"371","first-page":"660","unstructured":null,"article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(15)00068-9","key":"10.1053/j.gastro.2025.09.038_bib143","year":"2015","issue":null,"author":"Khanna","volume":"386","first-page":"1825","unstructured":null,"article-title":"Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1016/S2468-1253(24)00034-7","key":"10.1053/j.gastro.2025.09.038_bib144","year":"2024","issue":null,"author":"Noor","volume":"9","first-page":"415","unstructured":null,"article-title":"A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial","journal-title":"Lancet Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(17)30317-3","key":"10.1053/j.gastro.2025.09.038_bib145","year":"2017","issue":null,"author":"Kugathasan","volume":"389","first-page":"1710","unstructured":null,"article-title":"Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamanetworkopen.2020.7378","key":"10.1053/j.gastro.2025.09.038_bib146","year":"2020","issue":null,"author":"Adler","volume":"3","first-page":null,"unstructured":null,"article-title":"Association between steroid-sparing therapy and the risk of perianal fistulizing complications among young patients with Crohn disease","journal-title":"JAMA Netw Open","doi-asserted-by":"crossref"},{"DOI":"10.1136/gutjnl-2024-333280","key":"10.1053/j.gastro.2025.09.038_bib147","year":"2025","issue":null,"author":"Adler","volume":"74","first-page":"539","unstructured":null,"article-title":"Early tumour necrosis factor antagonist treatment prevents perianal fistula development in children with Crohn's disease: post hoc analysis of the RISK study","journal-title":"Gut","doi-asserted-by":"crossref"},{"DOI":"10.1542/peds.2021-052501","key":"10.1053/j.gastro.2025.09.038_bib148","year":"2022","issue":null,"author":"Constant","volume":"149","first-page":null,"unstructured":null,"article-title":"Delays related to prior authorization in inflammatory bowel disease","journal-title":"Pediatrics","doi-asserted-by":"crossref"},{"DOI":"10.1016/S2468-1253(21)00474-X","key":"10.1053/j.gastro.2025.09.038_bib149","year":"2022","issue":null,"author":"Danese","volume":"7","first-page":"294","unstructured":null,"article-title":"Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial","journal-title":"Lancet Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1053/j.gastro.2025.09.038_bib150","year":"2022","issue":"Suppl 8","author":"Jairath","volume":"10","first-page":"89","unstructured":null,"article-title":"A cluster-randomised controlled trial of an enhanced treatment algorithm for the management of Crohn’s disease: REACT-2","journal-title":"United European Gastroenterol J","doi-asserted-by":null},{"DOI":"10.1136/gutjnl-2019-318256","key":"10.1053/j.gastro.2025.09.038_bib151","year":"2020","issue":null,"author":"Panaccione","volume":"69","first-page":"658","unstructured":null,"article-title":"Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial","journal-title":"Gut","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(17)32641-7","key":"10.1053/j.gastro.2025.09.038_bib152","year":"2018","issue":null,"author":"Colombel","volume":"390","first-page":"2779","unstructured":null,"article-title":"Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2020.03.039","key":"10.1053/j.gastro.2025.09.038_bib153","year":"2020","issue":null,"author":"Ungaro","volume":"159","first-page":"139","unstructured":null,"article-title":"Deep remission at 1 year prevents progression of early Crohn's disease","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2021.11.030","key":"10.1053/j.gastro.2025.09.038_bib154","year":"2022","issue":null,"author":"Laharie","volume":"20","first-page":"2074","unstructured":null,"article-title":"Steroid-free deep remission at one year does not prevent Crohn's disease progression: long-term data from the TAILORIX Trial","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(14)61908-5","key":"10.1053/j.gastro.2025.09.038_bib155","year":"2015","issue":null,"author":"De Cruz","volume":"385","first-page":"1406","unstructured":null,"article-title":"Crohn's disease management after intestinal resection: a randomised trial","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2019.11.056","key":"10.1053/j.gastro.2025.09.038_bib156","year":"2020","issue":null,"author":"Christensen","volume":"18","first-page":"2518","unstructured":null,"article-title":"Histologic healing is more strongly associated with clinical outcomes in ileal Crohn's disease than endoscopic healing","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/apt.15190","key":"10.1053/j.gastro.2025.09.038_bib157","year":"2019","issue":null,"author":"Castiglione","volume":"49","first-page":"1026","unstructured":null,"article-title":"One-year clinical outcomes with biologics in Crohn's disease: transmural healing compared with mucosal or no healing","journal-title":"Aliment Pharmacol Ther","doi-asserted-by":"crossref"},{"DOI":"10.1097/MIB.0000000000001143","key":"10.1053/j.gastro.2025.09.038_bib158","year":"2017","issue":null,"author":"Fernandes","volume":"23","first-page":"1403","unstructured":null,"article-title":"Transmural healing is associated with improved long-term outcomes of patients with Crohn's disease","journal-title":"Inflamm Bowel Dis","doi-asserted-by":"crossref"},{"DOI":"10.14309/ajg.0000000000003465","key":"10.1053/j.gastro.2025.09.038_bib159","year":"2025","issue":null,"author":"Lichtenstein","volume":"120","first-page":"1225","unstructured":null,"article-title":"ACG Clinical Guideline: management of Crohn's disease in adults","journal-title":"Am J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1093/ecco-jcc/jjae091","key":"10.1053/j.gastro.2025.09.038_bib160","year":"2024","issue":null,"author":"Gordon","volume":"18","first-page":"1531","unstructured":null,"article-title":"ECCO Guidelines on Therapeutics in Crohn’s Disease: medical treatment","journal-title":"J Crohns Colitis","doi-asserted-by":"crossref"}],"short-title":[],"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,12]]}},"update-policy":"https://doi.org/10.1016/elsevier_cm_policy","alternative-id":["S0016508525060913"],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Gastroenterology"],"published-print":{"date-parts":[[2025,12]]},"reference-count":159,"published-online":null,"references-count":159,"short-container-title":["Gastroenterology"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1053/j.gastro.2025.09.038","is_oa":true,"title":"AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn’s Disease","updated":"2025-11-23T06:18:26+00:00","published_date":"2025-11-20","best_oa_location":{"url":"https://www.gastrojournal.org/article/S0016-5085(25)06091-3/pdf","pmh_id":null,"url_for_pdf":"https://www.gastrojournal.org/article/S0016-5085(25)06091-3/pdf","url_for_landing_page":"https://doi.org/10.1053/j.gastro.2025.09.038"}}},"created_at":"2025-12-04T03:42:26.941Z","updated_at":"2025-12-08T12:24:58.509Z","tags":[{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"condition","value":"Crohn's Disease","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"generic","value":"adalimumab","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"generic","value":"certolizumab pegol","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"generic","value":"guselkumab","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"generic","value":"infliximab","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"generic","value":"methotrexate","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"generic","value":"mirikizumab","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"generic","value":"risankizumab","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"generic","value":"upadacitinib","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"generic","value":"ustekinumab","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"generic","value":"vedolizumab","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"modality","value":"IL-12/23 Inhibitor","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"modality","value":"Integrin Inhibitor","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"modality","value":"JAK Inhibitor","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"modality","value":"Thiopurine","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"modality","value":"TNF Inhibitor","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"study_design","value":"Clinical Practice Guideline","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"warning","value":"As a living guideline, recommendations may change with updates.","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"warning","value":"Efficacy tiers (higher, intermediate, lower) are referenced without quantitative definition in the abstract; consult the full guideline for criteria.","value_numeric":null},{"paper_doi":"10.1053/j.gastro.2025.09.038","tag_type":"warning","value":"This is a clinical practice guideline summary, not primary trial data; effect sizes are not provided in the abstract.","value_numeric":null}],"summaries":{"what_studied":"An AGA living guideline used the GRADE framework to issue pharmacologic recommendations for adults with moderate-to-severely active Crohn’s disease.","key_result":"The panel issued 16 recommendations (1 strong, 9 conditional, 6 knowledge gaps): it recommends infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab, or upadacitinib over no treatment, and suggests certolizumab pegol or vedolizumab over no treatment. It advises higher-efficacy agents first-line in advanced-therapy–naïve patients; after prior advanced therapy, it suggests higher-efficacy (adalimumab, risankizumab, guselkumab, upadacitinib) or intermediate-efficacy (ustekinumab, mirikizumab) over lower-efficacy (vedolizumab, certolizumab pegol); avoid thiopurine monotherapy for induction but consider it for maintenance, use subcutaneous not oral methotrexate, favor infliximab plus thiopurine over infliximab alone, and start with advanced therapy rather than step therapy with steroids/immunomodulators.","practice_takeaway":"For adult outpatients with moderate-to-severe Crohn’s disease, start with an advanced therapy and choose a higher-efficacy agent when naïve to advanced treatments; after prior exposure, avoid lower-efficacy options. Do not use thiopurines to induce remission, use subcutaneous methotrexate if chosen, and prefer infliximab plus a thiopurine over infliximab alone."}},{"doi":"10.1111/ijd.70092","pmid":"41115146","title":"Efficacy of Biologics for the Treatment of Moderate‐To‐Severe Plaque Psoriasis in the Asian Population: A Systematic Review and Network Meta‐Analysis","journal_title":"International Journal of Dermatology","journal_issn":"0011-9059","published_at":"2025-10-20T00:00:00.000Z","url":"https://doi.org/10.1111/ijd.70092","source_score":15,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-10-25","doi":"10.1111/ijd.70092","days":"14","issn":"0011-9059","rank":"9","field":"Clinical Medicine","score":"15","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1111/ijd.70092","title":"Efficacy of Biologics for the Treatment of Moderate-To-Severe Plaque Psoriasis in the Asian Population: A Systematic Review and Network Meta-Analysis.","journal":"International journal of dermatology","methods":"","results":"","abstract":"$3e","keywords":["Asian population","SOC","biologics","meta‐analysis","psoriasis","skin of color","systematic review","tildrakizumab"],"pubmed_id":"41115146","conclusions":"","publication_date":"2025-10-20T00:00:00"},"crossref":{"DOI":"10.1111/ijd.70092","URL":"https://doi.org/10.1111/ijd.70092","ISSN":["0011-9059","1365-4632"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijd.70092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Efficacy of Biologics for the Treatment of Moderate‐To‐Severe Plaque Psoriasis in the Asian Population: A Systematic Review and Network Meta‐Analysis"],"author":[{"given":"Akihiko","family":"Asahina","sequence":"first","affiliation":[{"name":"The Jikei University School of Medicine Tokyo Japan"}]},{"given":"Mir Sohail","family":"Fazeli","sequence":"additional","affiliation":[{"name":"Evidinno Outcomes Research Inc Vancouver Canada"}]},{"given":"Robyn","family":"Kendall","sequence":"additional","affiliation":[{"name":"Evidinno Outcomes Research Inc Vancouver Canada"}]},{"given":"Gopika","family":"Balasubramanian","sequence":"additional","affiliation":[{"name":"Evidinno Outcomes Research Inc Vancouver Canada"}]},{"given":"Paul","family":"Serafini","sequence":"additional","affiliation":[{"name":"Evidinno Outcomes Research Inc Vancouver Canada"}]},{"given":"Asif","family":"Shaikh","sequence":"additional","affiliation":[{"name":"Sun Pharmaceutical Industries, Inc. Princeton New Jersey USA"}]},{"given":"Ranga","family":"Gogineni","sequence":"additional","affiliation":[{"name":"Sun Pharmaceutical Industries, Inc. Princeton New Jersey USA"}]},{"given":"Jianzhong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital Beijing China"}]}],"funder":[{"id":[{"id":"10.13039/501100013671","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100013671","name":"Sun Pharma","doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2025,10,20]]},"member":"311","prefix":"10.1111","source":"Crossref","volume":null,"archive":["Portico"],"created":{"date-time":"2025-10-20T15:39:01Z","timestamp":1760974741000,"date-parts":[[2025,10,20]]},"indexed":{"date-time":"2025-10-20T16:38:54Z","timestamp":1760978334520,"date-parts":[[2025,10,20]]},"license":[{"URL":"http://onlinelibrary.wiley.com/termsAndConditions#vor","start":{"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000,"date-parts":[[2025,10,20]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":"$3f","language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1111/ijd.70092"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-05-15"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-09-23"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2025-10-20"}],"deposited":{"date-time":"2025-10-20T15:39:04Z","timestamp":1760974744000,"date-parts":[[2025,10,20]]},"issn-type":[{"type":"print","value":"0011-9059"},{"type":"electronic","value":"1365-4632"}],"published":{"date-parts":[[2025,10,20]]},"publisher":"Wiley","reference":[{"DOI":"10.1038/nature05663","key":"e_1_2_10_2_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2340/00015555-3386","key":"e_1_2_10_3_1","year":"2020","issue":"3","author":"Reid C.","volume":"100","first-page":null,"unstructured":null,"article-title":"Psoriasis and Treatment: Past, Present and Future Aspects","journal-title":"Acta Dermato‐Venereologica","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2015.02.003","key":"e_1_2_10_4_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2010.11.055","key":"e_1_2_10_5_1","year":"2011","issue":"1","author":"American Academy of Dermatology Work Group","volume":"65","first-page":"137","unstructured":null,"article-title":"Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis: Section 6. Guidelines of Care for the Treatment of Psoriasis and Psoriatic Arthritis: Case‐Based Presentations and Evidence‐Based Conclusions","journal-title":"Journal of the American Academy of Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1007/s12325-022-02065-w","key":"e_1_2_10_6_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2019.4029","key":"e_1_2_10_7_1","year":"2020","issue":"3","author":"Armstrong A. W.","volume":"156","first-page":"258","unstructured":null,"article-title":"Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta‐Analysis","journal-title":"JAMA Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1371/journal.pone.0220868","key":"e_1_2_10_8_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.17448","key":"e_1_2_10_9_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s13555-022-00843-6","key":"e_1_2_10_10_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/jrsm.1432","key":"e_1_2_10_11_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1136/bmj.l4898","key":"e_1_2_10_12_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1177/0272989X12458724","key":"e_1_2_10_13_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/sim.6475","key":"e_1_2_10_14_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1467-9868.00353","key":"e_1_2_10_15_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_10_16_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“HUMIRA (Adalimumab) Prescribing Information ”(2021) http://www.rxabbvie.com/pdf/humira.pdf.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_17_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“CIMZIA (Cetrolizumab Pegol) Prescribing Information ”(2024) https://www.cimziahcp.com/full‐prescribing‐info.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_18_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“Remicade (Infliximab) Prescribing Information ”(2021) https://www.janssenlabels.com/package‐insert/product‐monograph/prescribing‐information/REMICADE‐pi.pdf.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_19_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“Bimzelx (Bimekizumab) Prescribing Information ”(2024) https://www.bimzelxhcp.com/prescribing‐information.pdf?_gl=1%2Athjj0v%2A_ga%2ANDUxMjQ1OTQ3LjE3Mjk2Njc5MjA.%2A_ga_CKX2D73W9W%2AMTczMTQwMjY0Ni41MS4xLjE3MzE0MDQ3MTguMC4wLjA.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_20_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“SILIQ (Brodalumab) Prescribing Information ”(2024) https://www.bauschhealth.com/Portals/25/Pdf/PI/Siliq‐pi.pdf.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_21_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“TALTZ (Ixekizumab) Prescribing Information ”(2024) http://uspl.lilly.com/taltz/taltz.html?s=pi.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_22_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“Cosentyx (Secukinumab) Prescribing Information ”(2024) https://www.novartis.com/us‐en/sites/novartis_us/files/cosentyx.pdf.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_23_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“Tremfya (Guselkumab) Prescribing Information ”(2024) https://www.janssenlabels.com/package‐insert/product‐monograph/prescribing‐information/TREMFYA‐pi.pdf.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_24_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“Skyrizi (Risankizumab) Prescribing Information ”(2024) https://www.rxabbvie.com/pdf/skyrizi_pi.pdf.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_25_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“ILUMYA (Tildrakizumab) Prescribing Information ”(2022) https://www.ilumya.com/Sun_Pharma_ILUMYA_US_Prescribing_Information_.pdf.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_26_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"“Stelara (Ustekinumab) Prescribing Information ”(2019) https://www.janssenlabels.com/package‐insert/product‐monograph/prescribing‐information/STELARA‐pi.pdf.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1111/j.1346-8138.2009.00748.x","key":"e_1_2_10_27_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.13746","key":"e_1_2_10_28_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s13555-021-00520-0","key":"e_1_2_10_29_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_10_30_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Clinicaltrials.gov “NCT03051217. A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis ”https://clinicaltrials.gov/study/NCT03051217.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/j.jdermsci.2010.04.014","key":"e_1_2_10_31_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_10_32_1","year":"2012","issue":"11","author":"Yang H. Z.","volume":"125","first-page":"1845","unstructured":null,"article-title":"Infliximab Monotherapy for Chinese Patients With Moderate to Severe Plaque Psoriasis: A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Trial","journal-title":"Chinese Medical Journal","doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_33_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Clinicaltrials.gov “NCT01177800. A Study to Evaluate Safety and Efficacy of Infliximab in Chinese Participants With Moderate to Severe Plaque‐Type Psoriasis ”(2025) https://clinicaltrials.gov/study/NCT01177800.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1007/s13555-022-00883-y","key":"e_1_2_10_34_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jdermsci.2015.10.009","key":"e_1_2_10_35_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.15733","key":"e_1_2_10_36_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.13927","key":"e_1_2_10_37_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1097/JD9.0000000000000244","key":"e_1_2_10_38_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.12668","key":"e_1_2_10_39_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.13900","key":"e_1_2_10_40_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1097/CM9.0000000000001163","key":"e_1_2_10_41_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.14504","key":"e_1_2_10_42_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.14941","key":"e_1_2_10_43_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.15789","key":"e_1_2_10_44_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1097/CM9.0000000000002873","key":"e_1_2_10_45_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jdermsci.2011.05.005","key":"e_1_2_10_46_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1346-8138.2011.01347.x","key":"e_1_2_10_47_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_10_48_1","year":"2013","issue":"2","author":"Zhu X.","volume":"12","first-page":"166","unstructured":null,"article-title":"Efficacy and Safety of Ustekinumab in Chinese Patients With Moderate to Severe Plaque‐Type Psoriasis: Results From a Phase 3 Clinical Trial (LOTUS)","journal-title":"Journal of Drugs in Dermatology","doi-asserted-by":null},{"DOI":"10.1016/S0140-6736(17)31279-5","key":"e_1_2_10_49_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.19866","key":"e_1_2_10_50_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_10_51_1","year":"2021","issue":null,"author":"Burlando M.","volume":"10","first-page":null,"unstructured":null,"article-title":"Treatment of Moderate‐To‐Severe Plaque Psoriasis With Tildrakizumab in the Real‐Life Setting","journal-title":"Drugs in Context","doi-asserted-by":null},{"DOI":"10.1111/jdv.19229","key":"e_1_2_10_52_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.15763","key":"e_1_2_10_53_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2016.10.017","key":"e_1_2_10_54_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2016.11.042","key":"e_1_2_10_55_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2016.11.041","key":"e_1_2_10_56_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(18)31713-6","key":"e_1_2_10_57_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_10_58_1","year":"2023","issue":"7","author":"Sbidian E.","volume":"7","first-page":null,"unstructured":null,"article-title":"Systemic Pharmacological Treatments for Chronic Plaque Psoriasis: A Network Meta‐Analysis","journal-title":"Cochrane Database of Systematic Reviews","doi-asserted-by":null},{"DOI":"10.1007/s13555-025-01423-0","key":"e_1_2_10_59_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.xjidi.2024.100261","key":"e_1_2_10_60_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1111/ijd.70092"],"article-number":"ijd.70092","content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["International Journal of Dermatology"],"reference-count":59,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,10,20]]},"references-count":59,"short-container-title":["Int J Dermatology"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1111/ijd.70092","is_oa":false,"title":"Efficacy of Biologics for the Treatment of Moderate‐To‐Severe Plaque Psoriasis in the Asian Population: A Systematic Review and Network Meta‐Analysis","updated":"2025-10-21T16:47:13+00:00","published_date":"2025-10-20","best_oa_location":null}},"created_at":"2025-10-27T13:37:43.000Z","updated_at":"2025-11-05T07:41:18.588Z","tags":[{"paper_doi":"10.1111/ijd.70092","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"condition","value":"Plaque Psoriasis","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"generic","value":"tildrakizumab","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"modality","value":"IL-12/23 Inhibitor","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"modality","value":"IL-17 Inhibitor","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"modality","value":"TNF Inhibitor","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"study_design","value":"Systematic Review and Network Meta-Analysis","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"warning","value":"Comparative effect sizes and credible intervals are not provided; “comparable” at Week 28 is qualitative in the abstract.","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"warning","value":"Safety results were within scope but not summarized in the abstract.","value_numeric":null},{"paper_doi":"10.1111/ijd.70092","tag_type":"warning","value":"Total number of participants across trials is not reported in the abstract.","value_numeric":null}],"summaries":{"what_studied":"Systematic review and Bayesian network meta-analysis of 19 randomized trials from China, Japan, Korea, and Taiwan comparing tildrakizumab with 10 other biologics in adult Asian patients with moderate-to-severe plaque psoriasis over 12–28 weeks, using PASI 75/90/100 and PGA 0/1.","key_result":"At Week 12, tildrakizumab showed lower efficacy than other biologics. From Weeks 12 to 28, PASI responses with tildrakizumab increased from 60.77%→81.84% (PASI 75), 38.54%→71.23% (PASI 90), and 6.97%→22.64% (PASI 100); by Week 28, efficacy was comparable to TNFα, IL-17, IL-12/23, and other IL-23 inhibitors.","practice_takeaway":"For Asian adults starting tildrakizumab, expect slower early clearance by 12 weeks but marked gains by 28 weeks, reaching parity with other biologics. Its sustained improvement and low dosing frequency support it as an effective option for moderate-to-severe plaque psoriasis."}},{"doi":"10.1001/jamadermatol.2025.2714","pmid":"40768223","title":"Biopharmaceutical Switching in Psoriasis Treatment","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2025-08-06T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2025.2714","source_score":82,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-10-19","doi":"10.1001/jamadermatol.2025.2714","days":"30","issn":"2168-6068","rank":"6","field":"Clinical Medicine","score":"82","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2025.2714","title":"Biopharmaceutical Switching in Psoriasis Treatment: A Systematic Review and Meta-Analysis.","journal":"JAMA dermatology","methods":"","results":"Twenty-four RCTs involving 12 661 patients with psoriasis and 8 switching categories were analyzed. Significant differences observed in PASI 90 between week 4 and week 0 (odds ratio [OR], 6.53; 95% CI, 2.58-16.51). Substantial disparities were noted across various PASI response metrics, specifically PASI 90 (OR, 28.61; 95% CI, 12.89-63.47), PASI 75 (OR, 11.11; 95% CI, 5.95-20.75), and PASI 100 (OR, 18.76; 95% CI, 8.37-42.01). No difference exists in safety outcomes between the end point and week 0, including in serious AEs (OR, 1.63; 95% CI, 0.72-3.69), severe AEs (OR, 1.40; 95% CI, 0.61-3.26), and treatment-related AEs (OR, 1.79; 95% CI, 0.41-7.88). The highest risk of infection was associated with switching from anti-TNF-α agents to anti-interleukin (IL)-23p19, anti-IL-17A, or anti-IL-12/23p40 agents, with infection rates of 0.62%, 0.54% and 0.39%, respectively.","abstract":"$40","keywords":[],"pubmed_id":"40768223","conclusions":"","publication_date":"2025-08-06T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2025.2714","URL":"https://doi.org/10.1001/jamadermatol.2025.2714","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2837167/jamadermatology_zhang_2025_oi_250038_1760475172.18406.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"1029","type":"journal-article","issue":"10","score":1,"title":["Biopharmaceutical Switching in Psoriasis Treatment"],"author":[{"given":"Miao","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China"},{"name":"Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China"}]},{"given":"Seokgyeong","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China"},{"name":"Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China"}]},{"given":"Qingyun","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China"}]},{"given":"Xiaoying","family":"Sun","sequence":"additional","affiliation":[{"name":"Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China"}]},{"given":"Yaqiong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China"}]},{"given":"Ying","family":"Luo","sequence":"additional","affiliation":[{"name":"Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China"}]},{"given":"Liu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China"},{"name":"Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China"}]},{"given":"Jiao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China"},{"name":"Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China"}]},{"given":"Chunxiao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China"},{"name":"Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China"}]},{"given":"Naixuan","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China"},{"name":"Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China"}]},{"given":"Juntang","family":"Yan","sequence":"additional","affiliation":[{"name":"School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China"},{"name":"Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China"}]}],"issued":{"date-parts":[[2025,10,1]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":"161","created":{"date-time":"2025-08-06T15:00:39Z","timestamp":1754492439000,"date-parts":[[2025,8,6]]},"indexed":{"date-time":"2025-10-16T00:52:14Z","timestamp":1760575934867,"date-parts":[[2025,10,16]]},"subject":[],"abstract":"$41","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2837167"}},"subtitle":["A Systematic Review and Meta-Analysis"],"deposited":{"date-time":"2025-10-15T15:02:25Z","timestamp":1760540545000,"date-parts":[[2025,10,15]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2025,10,1]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1038/nrd1607","key":"doi250038r1","year":"2005","issue":"1","author":"Gottlieb","volume":"4","first-page":"19","unstructured":null,"article-title":"Psoriasis: emerging therapeutic strategies.","journal-title":"Nat Rev Drug Discov","doi-asserted-by":"publisher"},{"DOI":"10.1080/17512433.2020.1767590","key":"doi250038r2","year":"2020","issue":"5","author":"Tsai","volume":"13","first-page":"493","unstructured":null,"article-title":"Switching biologics in psoriasis - practical guidance and evidence to support.","journal-title":"Expert Rev Clin Pharmacol","doi-asserted-by":"publisher"},{"DOI":"10.3109/09546634.2013.826341","key":"doi250038r3","year":"2014","issue":"1","author":"Levin","volume":"25","first-page":"78","unstructured":null,"article-title":"Biologic fatigue in psoriasis.","journal-title":"J Dermatolog Treat","doi-asserted-by":"publisher"},{"DOI":"10.1046/j.1365-2230.2001.00829.x","key":"doi250038r4","year":"2001","issue":"4","author":"van de Kerkhof","volume":"26","first-page":"356","unstructured":null,"article-title":"Therapeutic strategies: rotational therapy and combinations.","journal-title":"Clin Exp Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.autrev.2024.103530","key":"doi250038r5","year":"2024","issue":"4","author":"Sun","volume":"23","first-page":null,"unstructured":null,"article-title":"Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: an analysis of current evidence.","journal-title":"Autoimmun Rev","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2018.11.057","key":"doi250038r6","year":"2019","issue":"4","author":"Menter","volume":"80","first-page":"1029","unstructured":null,"article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1038/s41598-023-40222-5","key":"doi250038r7","year":"2023","issue":"1","author":"de Oliveira Ascef","volume":"13","first-page":"13699","unstructured":null,"article-title":"Impact of switching between reference biologics and biosimilars of tumour necrosis factor inhibitors for rheumatoid arthritis: a systematic review and network meta-analysis.","journal-title":"Sci Rep","doi-asserted-by":"publisher"},{"DOI":"10.1136/annrheumdis-2017-211937","key":"doi250038r8","year":"2018","issue":"2","author":"Kay","volume":"77","first-page":"165","unstructured":null,"article-title":"Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases.","journal-title":"Ann Rheum Dis","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2016.02.1221","key":"doi250038r9","year":"2016","issue":"3","author":"Yamauchi","volume":"75","first-page":"612","unstructured":null,"article-title":"Systematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2020.11.022","key":"doi250038r10","year":"2021","issue":"2","author":"Blauvelt","volume":"85","first-page":"360","unstructured":null,"article-title":"Long-term efficacy and safety of ixekizumab: a 5-year analysis of the UNCOVER-3 randomized controlled trial.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2230.1994.tb01167.x","key":"doi250038r11","year":"1994","issue":"3","author":"Finlay","volume":"19","first-page":"210","unstructured":null,"article-title":"Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use.","journal-title":"Clin Exp Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.3109/09546634.2015.1114567","key":"doi250038r12","year":"2016","issue":"4","author":"Mathias","volume":"27","first-page":"322","unstructured":null,"article-title":"Measurement properties of a patient-reported outcome measure assessing psoriasis severity: The psoriasis symptoms and signs diary.","journal-title":"J Dermatolog Treat","doi-asserted-by":"publisher"},{"DOI":"10.1093/bjd/ljac021","key":"doi250038r13","year":"2023","issue":"1","author":"Thaçi","volume":"188","first-page":"22","unstructured":null,"article-title":"Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa2102388","key":"doi250038r14","year":"2021","issue":"2","author":"Warren","volume":"385","first-page":"130","unstructured":null,"article-title":"Bimekizumab versus adalimumab in plaque psoriasis.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2023.04.063","key":"doi250038r15","year":"2023","issue":"3","author":"Strober","volume":"89","first-page":"486","unstructured":null,"article-title":"Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.15750","key":"doi250038r16","year":"2018","issue":"1","author":"Langley","volume":"178","first-page":"114","unstructured":null,"article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1093/bjd/ljac089","key":"doi250038r17","year":"2023","issue":"3","author":"Kokolakis","volume":"188","first-page":"330","unstructured":null,"article-title":"Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.17454","key":"doi250038r18","year":"2019","issue":"5","author":"Reich","volume":"180","first-page":"1039","unstructured":null,"article-title":"Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2021.11.004","key":"doi250038r19","year":"2022","issue":"4","author":"Blauvelt","volume":"86","first-page":"827","unstructured":null,"article-title":"Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2018.05.032","key":"doi250038r20","year":"2018","issue":"5","author":"Leonardi","volume":"79","first-page":"824","unstructured":null,"article-title":"Maintenance of skin clearance with ixekizumab treatment of psoriasis: three-year results from the UNCOVER-3 study.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.15921","key":"doi250038r21","year":"2020","issue":"2","author":"Lebwohl","volume":"34","first-page":"301","unstructured":null,"article-title":"Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study.","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(19)30952-3","key":"doi250038r22","year":"2019","issue":"10198","author":"Reich","volume":"394","first-page":"576","unstructured":null,"article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.19866","key":"doi250038r23","year":"2021","issue":"2","author":"Thaci","volume":"185","first-page":"323","unstructured":null,"article-title":"Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2).","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi250038r25","year":"1998","issue":"1","author":"Noble","volume":"58","first-page":"163","unstructured":null,"article-title":"Diagnosis and management of common tinea infections.","journal-title":"Am Fam Physician","doi-asserted-by":null},{"DOI":"10.1080/17476348.2021.1988569","key":"doi250038r26","year":"2021","issue":"12","author":"Wang","volume":"15","first-page":"1517","unstructured":null,"article-title":"Management of acute upper respiratory tract infection: the role of early intervention.","journal-title":"Expert Rev Respir Med","doi-asserted-by":"publisher"},{"DOI":"10.1164/rccm.202011-4239PP","key":"doi250038r27","year":"2021","issue":"2","author":"Behr","volume":"204","first-page":"142","unstructured":null,"article-title":"Latent tuberculosis: two centuries of confusion.","journal-title":"Am J Respir Crit Care Med","doi-asserted-by":"publisher"},{"DOI":"10.1038/nrurol.2010.190","key":"doi250038r28","year":"2010","issue":"12","author":"Foxman","volume":"7","first-page":"653","unstructured":null,"article-title":"The epidemiology of urinary tract infection.","journal-title":"Nat Rev Urol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.crohns.2012.06.024","key":"doi250038r29","year":"2013","issue":"4","author":"Aubin","volume":"7","first-page":"257","unstructured":null,"article-title":"The complexity of adverse side-effects to biological agents.","journal-title":"J Crohns Colitis","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.17318","key":"doi250038r30","year":"2019","issue":"2","author":"Langley","volume":"180","first-page":"306","unstructured":null,"article-title":"Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi250038r31","year":"2018","issue":"8","author":"Griffiths","volume":"17","first-page":"826","unstructured":null,"article-title":"Long-term efficacy of guselkumab for the treatment of moderate-to-severe psoriasis: results from the phase 3 VOYAGE 1 trial through two years.","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1007/s40257-016-0246-9","key":"doi250038r32","year":"2017","issue":"2","author":"Blauvelt","volume":"18","first-page":"273","unstructured":null,"article-title":"Efficacy and safety of switching to ixekizumab in etanercept non-responders: a subanalysis from two phase III randomized clinical trials in moderate-to-severe plaque psoriasis (UNCOVER-2 and -3).","journal-title":"Am J Clin Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.18484","key":"doi250038r33","year":"2020","issue":"6","author":"Kimball","volume":"182","first-page":"1359","unstructured":null,"article-title":"Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ad.2017.02.005","key":"doi250038r34","year":"2017","issue":"6","author":"Valenzuela","volume":"108","first-page":"550","unstructured":null,"article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis: Subgroup analysis of Latin American patients in the phase 3 randomized UNCOVER-3 study.","journal-title":"Actas Dermosifiliogr","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2017.06.153","key":"doi250038r35","year":"2017","issue":"5","author":"Blauvelt","volume":"77","first-page":"855","unstructured":null,"article-title":"Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3).","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1080/09546634.2020.1782817","key":"doi250038r36","year":"2022","issue":"2","author":"Griffiths","volume":"33","first-page":"848","unstructured":null,"article-title":"Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1.","journal-title":"J Dermatolog Treat","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2019.06.232","key":"doi250038r37","year":"2019","issue":"4","author":"Ryan","volume":"81","first-page":"AB55","unstructured":null,"article-title":"Efficacy of switching to risankizumab compared with continued adalimumab treatment in patients with moderate-to-severe plaque psoriasis.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2016.11.042","key":"doi250038r38","year":"2017","issue":"3","author":"Reich","volume":"76","first-page":"418","unstructured":null,"article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa0810652","key":"doi250038r39","year":"2010","issue":"2","author":"Griffiths","volume":"362","first-page":"118","unstructured":null,"article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1007/s40257-020-00555-7","key":"doi250038r40","year":"2020","issue":"6","author":"Reich","volume":"21","first-page":"881","unstructured":null,"article-title":"Maintenance of response through up to 4 years of continuous guselkumab treatment of psoriasis in the VOYAGE 2 phase 3 study.","journal-title":"Am J Clin Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.20568","key":"doi250038r41","year":"2021","issue":"6","author":"Reich","volume":"185","first-page":"1146","unstructured":null,"article-title":"Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.2340/actadv.v104.41053","key":"doi250038r42","year":"2024","issue":null,"author":"Errichetti","volume":"104","first-page":null,"unstructured":null,"article-title":"Patients with persistent mild psoriasis after treatment with ustekinumab achieved greater improvements in skin clearance and patient-reported outcomes after switching to guselkumab in the phase 3 NAVIGATE Trial.","journal-title":"Acta Derm Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1155/2022/2442603","key":"doi250038r43","year":"2022","issue":null,"author":"Feng","volume":"2022","first-page":null,"unstructured":null,"article-title":"Risk of Candida infection and serious infections in patients with moderate-to-severe psoriasis receiving biologics: a systematic review and meta-analysis of randomized controlled trials.","journal-title":"Int J Clin Pract","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.chom.2012.04.008","key":"doi250038r44","year":"2012","issue":"5","author":"Hernández-Santos","volume":"11","first-page":"425","unstructured":null,"article-title":"Th17 cells in immunity to Candida albicans.","journal-title":"Cell Host Microbe","doi-asserted-by":"publisher"},{"DOI":"10.2340/00015555-3386","key":"doi250038r45","year":"2020","issue":"3","author":"Reid","volume":"100","first-page":null,"unstructured":null,"article-title":"Psoriasis and treatment: past, present and future aspects.","journal-title":"Acta Derm Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ad.2015.04.013","key":"doi250038r46","year":"2015","issue":"8","author":"Carrascosa","volume":"106","first-page":"638","unstructured":null,"article-title":"Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time.","journal-title":"Actas Dermosifiliogr","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2023.1338","key":"doi250038r47","year":"2023","issue":"7","author":"Phan","volume":"159","first-page":"763","unstructured":null,"article-title":"Biosimilars for the treatment of psoriasis: a systematic review of clinical trials and observational studies.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s40261-017-0603-3","key":"doi250038r48","year":"2018","issue":"3","author":"Hu","volume":"38","first-page":"191","unstructured":null,"article-title":"A review of switching biologic agents in the treatment of moderate-to-severe plaque psoriasis.","journal-title":"Clin Drug Investig","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaci.2023.03.035","key":"doi250038r49","year":"2023","issue":"3","author":"Cole","volume":"152","first-page":"783","unstructured":null,"article-title":"Differential regulation of IL-17A and IL-17F via STAT5 contributes to psoriatic disease.","journal-title":"J Allergy Clin Immunol","doi-asserted-by":"publisher"},{"DOI":"10.3389/fimmu.2023.1191782","key":"doi250038r50","year":"2023","issue":null,"author":"Navarro-Compán","volume":"14","first-page":null,"unstructured":null,"article-title":"The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases.","journal-title":"Front Immunol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi250038r24","year":"2025","issue":null,"author":"Taylor","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"published-print":{"date-parts":[[2025,10,1]]},"reference-count":50,"published-online":null,"references-count":50,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1001/jamadermatol.2025.2714","is_oa":false,"title":"Biopharmaceutical Switching in Psoriasis Treatment","updated":"2025-08-17T18:46:03+00:00","published_date":"2025-08-06","best_oa_location":null}},"created_at":"2025-09-19T17:59:11.167Z","updated_at":"2025-11-13T07:40:24.859Z","tags":[{"paper_doi":"10.1001/jamadermatol.2025.2714","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2714","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2714","tag_type":"condition","value":"Plaque Psoriasis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2714","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2714","tag_type":"modality","value":"Biologic","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2714","tag_type":"modality","value":"IL-12/23 Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2714","tag_type":"modality","value":"IL-17 Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2714","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2714","tag_type":"modality","value":"TNF Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2714","tag_type":"sample_size","value":"n=12,661","value_numeric":12661},{"paper_doi":"10.1001/jamadermatol.2025.2714","tag_type":"study_design","value":"Systematic Review and Meta-analysis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2714","tag_type":"warning","value":"Effect sizes compare outcomes at week 4 or study end to baseline rather than head-to-head between specific switching strategies.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2714","tag_type":"warning","value":"Safety outcomes show wide confidence intervals, indicating imprecision.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2714","tag_type":"warning","value":"The abstract does not report follow-up duration, individual drug data, switching protocols, or PROM results.","value_numeric":null}],"summaries":{"what_studied":"Systematic review and meta-analysis of 24 RCTs (n=12,661) in adults with plaque psoriasis evaluating effectiveness and safety when switching from an initial biologic to another (within or across classes); searches through January 25, 2025. The prespecified primary end point was PASI 90; secondary outcomes included PASI 75/100, global assessments, BSA ≤1%, PROMs, and safety events.","key_result":"PASI 90 improved by week 4 vs baseline (OR 6.53; 95% CI 2.58-16.51) and by end point vs baseline (OR 28.61; 95% CI 12.89-63.47); PASI 75 (OR 11.11; 95% CI 5.95-20.75) and PASI 100 (OR 18.76; 95% CI 8.37-42.01) also improved. No differences were seen in serious AEs (OR 1.63; 95% CI 0.72-3.69), severe AEs (OR 1.40; 95% CI 0.61-3.26), or treatment-related AEs (OR 1.79; 95% CI 0.41-7.88); infection rates were highest when switching from anti–TNF-α to IL-23p19 (0.62%), IL-17A (0.54%), or IL-12/23p40 (0.39%).","limitations":"Authors note the need for larger patient cohorts and longer follow-up to confirm findings. The abstract does not detail follow-up duration, switching regimens, or PROM results, and safety estimates have wide CIs.","practice_takeaway":"For adults with plaque psoriasis who fail a biologic, switching—especially across classes—can yield high PASI responses without an observed increase in serious adverse events; monitor for infections, particularly after switching from anti–TNF-α to IL-23, IL-17, or IL-12/23 agents."}}],"initialOffset":23,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"modality","value":"IL-12/23 Inhibitor"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Modalities","href":"/hub/tag/modality"},{"name":"IL-12/23 Inhibitor"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"modality","hub_tag_value":"IL-12/23 Inhibitor"}}}]] 2b:null

Papers

Papers